Tržby společnosti Marvell ve 2. čtvrtletí fiskálního roku 2027 meziročně vzrostly o 36,55 % na 2,739 mld. USD, k čemuž přispěl 46% růst segmentu datových center.
Marvell stock has surged more than 200% in a year on the back of explosive AI data center demand, but whether that momentum carries a $5,000 investment higher or leaves it worse off depends on forces that could shift fast.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
If you put $5,000 into Marvell Technology (NASDAQ:MRVL | MRVL Price Prediction) today, what could it be worth by 2031? Shares traded at $269.87 in early trading, after a 213.75% gain over the past year.
The rally comes from AI data center demand that management says is still speeding up, and that is why it makes sense to look five years ahead.
What Your $5,000 Could Become by 2031 Under the model’s central scenario, a $5,000 investment could be worth about $6,763.50 by 2031, a total return of 35.27%.
That figure rests on a projected five-year share price of $368.34, measured from the model’s starting price of $272.29. The annualized return comes to 6.23%. The model rates its confidence at 0.9, a level it views high.
Bull, Base and Bear Scenarios for a $5,000 Stake Scenario 2031 Target Price Total Return Value of $5,000 Bull $514.53 88.96% $9,448 Base $368.34 35.27% $6,763.50 Bear $222.03 -18.46% $4,077 Wall Street is bullish. Analysts list 8 Strong Buy ratings, 32 Buys, 6 Holds and no Sell ratings, with a consensus price target of $293.88.
Over one year, the model’s base case calls for $293.18, or 7.67% upside. That is close to the analyst target, so most of the projected gain is expected to build gradually after the first year.
Three Drivers Behind the Target Data Center Revenue Keeps Accelerating Second-quarter fiscal 2027 revenue reached $2.739 billion, up 36.55% year over year and ahead of the $2.7068343 billion estimate. Data center sales rose 46% to $2.1715 billion and now make up 79% of revenue.
Management expects fiscal 2027 revenue to grow about 45% to roughly $12 billion. It also raised its fiscal 2028 growth outlook to about 50%. CEO Matt Murphy said: “AI-related bookings remain exceptionally robust, and we expect our revenue growth to accelerate further through the remainder of fiscal 2027.”
Custom Silicon and Google Deal Could Drive the Bull Case Marvell expanded its custom silicon partnership with Alphabet (NASDAQ:GOOGL) unit Google. The deal includes a warrant that lets Google buy up to 7% of Marvell’s shares if revenue targets are met. Management expects the custom business to more than double year over year in fiscal 2028.
It also confirmed a custom revenue path toward a “$10 billion kind of plus number” in fiscal 2029, and said the Google agreement raises that potential. Tuesday’s Investor Day in New York is expected to include a longer-term revenue framework, and that update could move the scenarios above.
Margins Are Widening Non-GAAP operating margin expanded to 36.6% from 34.8%, and non-GAAP EPS of $0.94 beat the 0.9289 estimate. Management expects the margin to reach its 38% to 40% long-term target range in the fourth quarter of fiscal 2027.
Guidance for the third quarter calls for $3.150 billion in revenue and non-GAAP EPS of $1.10, plus or minus 5 cents.
Risks That Could Shrink Your $5,000 A lot of growth is already in the price. Marvell trades at 90 times trailing earnings and 62 times forward earnings. Its beta of 2.253 means the stock tends to move about twice as much as the market.
Over the past 52 weeks it has traded as low as $70.64 and as high as $329.80. If growth slows, the bear case would leave your investment at $4,077.
Customer concentration: a small group of hyperscalers drives a large share of revenue, and any of them could cut spending or design chips in-house. Supply constraints: advanced wafers, substrates and test capacity are tight. Marvell plans about $1 billion in capacity prepayments to suppliers this fiscal year. Trade and tariffs: restrictions on Chinese customers and tariff uncertainty add risk. Balance sheet and dilution: long-term debt totals $4.963 billion. The Google warrant could dilute existing shareholders, and stock-based compensation rose to $207.6 million in the first quarter from $142.1 million a year earlier. Where a $5,000 Marvell Stake Could Land Under the projected scenarios, a $5,000 Marvell investment could be worth anywhere from $4,077 to $9,448 by 2031, with a base case of $6,763.50.
Over the next year, keep an eye on Investor Day targets, custom silicon ramps and whether hyperscalers keep spending at their current pace. The traits that showed up early in the biggest AI chip winners are the ones we cataloged in a free playbook here: The Next Nvidia Playbook. These are projections, not guarantees, and this is not investment advice.
Contact [email protected] for any questions or corrections.
NEAR v září vzrostl o 183 % z přibližně 1,80 USD na více než 5 USD. Spotový ETF fond Bitwise NEAR (NRR) v USA během prvního týdne přilákal 58 milionů USD.
Key Highlights The NEAR token surged from approximately $1.80 at the start of September to exceed $5, marking a 183% monthly increase. On September 29, Bitwise introduced the inaugural U.S. spot NEAR ETF (ticker: NRR), which accumulated $58 million during its opening week. A Grayscale analysis emphasized NEAR’s focus on “agentic commerce,” enabling AI agents to independently execute payments and commission tasks. Current trading levels place NEAR around $5.19, with immediate support identified at $5.13 and resistance between $5.39-$5.44. The MyNearWallet platform will cease operations on October 31, directing users to alternative solutions including Meteor Wallet and near.com. The NEAR Protocol token has delivered one of autumn’s most impressive cryptocurrency performances. Beginning September trading near the $1.80 level, the asset pushed beyond $5 as October arrived.
NEAR Price This upward movement translated into approximately 183% growth, based on figures referenced by Grayscale. The performance notably exceeded the wider AI-focused cryptocurrency segment, which registered 54% gains during the identical timeframe.
A substantial portion of the initial momentum originated in derivatives trading. Data from Santiment indicated that dollar-based open interest surged 119% during the period spanning September 13 through September 20.
Meanwhile, open interest calculated in NEAR tokens themselves expanded by just 21% within that same interval. This disparity indicates that leverage usage and token appreciation contributed more significantly than fresh position entries.
Funding rates elevated to approximately 1.6 times their two-month median level. Market participants have been monitoring chart patterns for indications of future direction.
Technical analyst Nebraskangooner identified an emerging pennant formation on NEAR’s chart, noting that traders should monitor this pennant pattern for the next significant directional move.
Spot market activity for NEAR also commenced on Hyperliquid during September 22-23. This development introduced direct NEAR/USDC pair trading alongside the platform’s existing perpetual contract market, where open interest approached $344 million.
The most significant development occurred September 29, when Bitwise unveiled America’s first spot NEAR exchange-traded fund. Trading on NYSE Arca under ticker symbol NRR, the fund carries a 0.75% annual management fee.
By October 6, the ETF had attracted approximately $58 million in assets during its inaugural week. Bitwise’s accompanying research established a $562.81 price projection for the year 2030.
AI Agent Infrastructure Shapes Investment Narrative The investment case for NEAR increasingly emphasizes AI agent functionality over general blockchain applications. Grayscale characterized the network as an infrastructure for agentic commerce, enabling autonomous agents to commission work and execute payments independently.
Grayscale names NEAR among the leaders of crypto's AI sector, calling it the "platform for agentic commerce."
NEAR was co-founded by @ilblackdragon, co-author of "Attention Is All You Need," the paper that introduced the transformer: the T in ChatGPT.https://t.co/YgPoTJVoMK
— NEAR Protocol (@NEARProtocol) October 5, 2026
The analysis highlighted NEAR’s chain abstraction capabilities, which enable agents to navigate multiple blockchains with reduced complexity. Additionally, co-founder Illia Polosukhin contributed to authoring the foundational Transformer architecture paper that underpins contemporary AI models.
On September 28, NEAR AI broadened its confidential-inference capabilities through an OpenRouter collaboration. Subsequently, NEAR One introduced SPICE, an architectural approach that decouples transaction execution from consensus mechanisms to enhance network scalability.
Market analyst Altcoin Sherpa expressed a more measured perspective, stating he would prefer to see additional consolidation over one to two weeks before another upward leg, emphasizing that NEAR’s trajectory remains heavily influenced by bitcoin’s movements.
$NEAR would love to see this chop and consolidate for another 1-2 weeks and then have a strong leg up. It's going to be bitcoin dependent imo but I still think near is a great coin pic.twitter.com/U7fGmHlqOw
— Altcoin Sherpa (@AltcoinSherpa) October 6, 2026
User Base Navigates Wallet Transition NEAR’s community confronts an operational change separate from price dynamics. MyNearWallet will discontinue service on October 31, with users redirected toward Meteor Wallet or near.com alternatives.
The transition process has included assisted migration tools since August, with feature restrictions beginning this month. User assets and staking arrangements remain secured on-chain throughout the changeover.
Trading activity has maintained momentum during this transition period. NEAR experienced a retreat to the $4.70-$4.80 range on October 5 before recovering to trade between $5.19 and $5.25 the following session.
Technical resistance is positioned near $5.39 to $5.44, while support maintains at $5.13. A decisive break above resistance could establish pathways toward $5.56 and subsequently $6.00.
The weekly Relative Strength Index for NEAR moderated to approximately 75 after approaching 85 in late September. The 50-day moving average is currently positioned near $2.90, well beneath today’s trading levels.
FDA zařadila plozasiran společnosti Arrowhead do programu STAR, což může zkrátit lhůtu pro posouzení žádosti o schválení léčby těžké hypertriglyceridemie na šest měsíců.
- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admissions and can be fatal.
We are committed to pursuing every potential opportunity to accelerate the process of bringing plozasiran to patients, and the FDA STAR Pilot program provides important benefits to sponsors with efficacy supplements.
Share The FDA STAR pilot program aims to shorten the time from the date of a complete sNDA submission to the action date for certain supplemental indications for already-approved drugs. To be granted entry in the STAR program, FDA must determine that clinical evidence from adequate and well-controlled investigation(s) indicates that the drug may demonstrate substantial improvement on a clinically relevant endpoint(s) over available therapies.
Once accepted into the STAR program, a supplemental application qualifies for a 6-month Priority Review compared to a 10-month standard review. In addition, FDA will generally target an “expedited review” for efficacy supplements in the STAR program, meaning an action at least 1 month before the Priority Review goal date is possible. The use of a Priority Review Voucher (PRV) is not necessary for programs that are granted entry in the STAR program, so Arrowhead retains the PRV previously purchased in August 2026.
“We are committed to pursuing every potential opportunity to accelerate the process of bringing plozasiran to patients, and the FDA STAR Pilot program provides important benefits to sponsors with efficacy supplements,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “In addition, earning Priority Review for plozasiran without the need to use a PRV gives us the option to redeploy our voucher for a future application or monetize it.”
Arrowhead is on schedule to submit a sNDA for plozasiran in sHTG to the FDA by year-end 2026 and plans to seek regulatory approval with additional global regulatory authorities thereafter. Plozasiran has received regulatory approval, as REDEMPLO®, in the United States, the European Union, China, Australia, and Canada as an adjunct to diet to reduce triglycerides in adults with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), which is the most severe form of sHTG.
About Severe Hypertriglyceridemia
Severe hypertriglyceridemia (sHTG) is characterized by triglyceride (TG) levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride rich lipoproteins (TRLs), particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of atherosclerotic cardiovascular disease (ASCVD). Limited treatment options exist to sustainably reduce TGs below guideline directed risk thresholds.
About REDEMPLO® (plozasiran)
REDEMPLO (plozasiran) is currently approved by the U.S. Food and Drug Administration, Health Canada, China’s National Medical Products Administration, the Australian Therapeutic Goods Administration, and by the European Commission as an adjunct to diet to reduce triglycerides for adults with FCS. REDEMPLO is the first and only siRNA treatment approved in these countries to be studied in both clinically diagnosed and genetically confirmed patients living with FCS.
REDEMPLO is designed to suppress the production of apolipoprotein C-III (APOC3), a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting APOC3 with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is self-administered via subcutaneous injection once every three months.
REDEMPLO has been granted Orphan Medicinal Product Designation by the EMA for the treatment of patients with FCS, and Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the U.S. FDA for the treatment of patients with FCS and was also granted Breakthrough Therapy designation by the U.S. FDA in severe hypertriglyceridemia.
Sanofi acquired the rights to develop and commercialize REDEMPLO in Greater China, with Arrowhead retaining rights to REDEMPLO in all geographies, outside of Greater China.
For more information about REDEMPLO, visit Our Medicines.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; and our beliefs and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Circle přidala Solanu do USDC Bridge, což umožňuje přímé převody nativního USDC mezi Solanou a 18 dalšími blockchainy prostřednictvím vlastního rozhraní Circle.
Circle has added Solana to its USDC Bridge, giving users a direct route to move native $USDC between Solana and 18 other blockchain ecosystems from a single, first-party interface.
What the Integration Does Circle's USDC Bridge at bridge(.)usdc(.)com now supports Solana, letting users move native USDC between Solana and 18 other chains through Circle's own interface. The key word is native:
That matters because wrapped tokens carry their own risks and add complexity for traders and developers.
Solana's addition is notable because
Why It Matters for Solana's Ecosystem The update removes a meaningful gap in Circle's own product suite. Previously, Solana users who wanted to move USDC cross-chain through CCTP had to rely on third-party apps built on top of the protocol. Now they can do it directly through Circle's interface, reducing friction and counterparty steps.
The timing reflects Solana's growing weight in the stablecoin market.
For developers, the update also means Solana apps and markets are now reachable through a unified bridge, simplifying the user journey for anyone moving liquidity into the ecosystem from Ethereum, Base, Arbitrum, or other supported networks.
Sources:
Solana Compass: Circle's USDC Bridge Adds Solana, Linking It to 18 Other Chains
Genfinity: Circle Launches USDC Bridge for Native Cross-Chain Stablecoin Transfers
The Block: Circle Rolls Out USDC Bridge for Native Cross-Chain Stablecoin Transfers
TLDR SOL is currently trading around $121, maintaining support above its 20, 50, 100 and 200-day exponential moving averages. Both daily and weekly timeframes identify $125 as critical resistance that could determine the next directional move. Chaikin Money Flow on the daily chart registers 0.23, indicating consistent accumulation. Total value locked in Solana’s DeFi ecosystem increased from approximately $5.6 billion to $6.7 billion during the September-October period. Derivatives open interest has surged past $7 billion, with significant liquidation zones concentrated around $115 and $125. Solana was changing hands at $121.44 as of Oct. 6, registering a modest 0.55% gain in the preceding 24-hour period. The digital asset has been range-bound for multiple trading sessions following a strong rebound in September.
Solana (SOL) Price Daily price action saw SOL reach an intraday peak of $122 before pulling back to a low of $118.88. This tight corridor has persisted for several days, with the late-September high establishing the immediate price ceiling.
From current levels, SOL remains approximately 3.5% beneath the $125 threshold highlighted on weekly charts. Reaching $150 would necessitate a rally of roughly 24% from present valuations.
Daily technical indicators show SOL maintaining a position above its 20-day EMA at $116.39 and 50-day EMA at $106.76. The longer-term 100-day and 200-day EMAs are positioned further below at $97.77 and $96.60 respectively.
Weekly Chart Highlights $125 as Critical Decision Point Analysis of the weekly TradingView chart identifies $125 as the primary pivot point according to the Murrey Math indicator. SOL was quoted at $120.77 on the weekly timeframe, hovering just beneath this crucial level.
The subsequent Murrey Math resistance is located at $156.25, representing the upper boundary of the established trading channel. On the downside, the corresponding support floor stands at $93.75.
The weekly Average Directional Index registered 30.21. This metric quantifies trend intensity rather than trajectory, providing no inherent bullish or bearish signal for October.
Market analyst Wealthmanager observed on X that SOL appears to be forming a contracting triangle pattern, characterized by descending highs and ascending lows compressing the trading range. The analyst noted that while no breakout has materialized, the setup suggests a significant move may be approaching.
$SOL is forming a tight triangle.
Price is making lower highs and higher lows as the range gets smaller.
No breakout yet. The next move could be close. pic.twitter.com/7akdUNGIXl
— Wealthmanager (@Wealthmanager) October 6, 2026
DeFi Metrics and Derivatives Interest Show Sustained Growth DeFiLlama statistics reveal that total value locked across Solana’s DeFi protocols expanded from approximately $5.6 billion in early September to roughly $6.7 billion by early October. Decentralized exchange volumes and active wallet counts remained robust throughout this interval.
According to CoinGlass tracking, Solana’s aggregate open interest in derivatives markets has pushed above the $7 billion threshold during this timeframe. Both long and short positions have experienced liquidations as SOL fluctuates near the $121 mark.
The one-month liquidation heatmap from CoinGlass reveals concentration zones between $115 and $116 beneath current pricing. Additional liquidation bands are visible near $112 and within the $104 to $105 range.
Source: Coinglass On the upside, the heatmap displays notable clusters between $123 and $125, with further accumulation near $126 to $127. These zones align closely with the weekly $125 pivot level.
The daily Supertrend indicator continues to flash green at $107.22, sitting approximately 11.3% below current market price. SOL has maintained its position above this dynamic support throughout recent consolidation.
Technical charts mark $113.05 as the primary support threshold on daily timeframes. A breakdown below this level could redirect attention toward the lower exponential moving averages.
Network performance metrics have also shown improvement. The Solana Foundation disclosed that mainnet slot times achieved 250 milliseconds on Sep. 18, with a planned reduction to 200 milliseconds targeted for epoch 1052.
Solana Foundation spustila Solana DvP, mechanismus dodání proti platbě, na jehož návrhu se podílela JPMorgan; systém umožňuje vypořádat obě strany obchodu v jediné transakci během několika sekund.
Is “institutional settlement, not adoption” becoming Solana’s next growth catalyst?
Institutional adoption is evolving beyond ETF flows, with on-chain infrastructure becoming an integral pillar of the TradFi narrative. In other words, fundamentals are starting to matter more as major financial players explore blockchain-based settlement.
With Solana and JPMorgan’s reported partnership, the L1 could be looking to position itself as one of the first networks onboarding TradFi into the world of on-chain markets.
As the post below demonstrates, the Solana foundation has just launched Solana DvP.
But the key here is “institutional settlement”, and unlike ETF flows or strategic accumulation, it’s a much deeper layer of institutional adoption, where institutions are actually “using” the blockchain to settle transactions.
Source: X As the Solana Foundation explains, institutions that have settled on-chain have typically used custom smart contracts for their transactions. The traditional settlement process can take up to one or two days to tie up capital.
With Solana DvP, both sides of a trade are executed in one transaction, so they either both settle, or they don’t, with settlement finality in seconds.
This is different from institutions getting exposure to SOL through ETFs or accumulation.
According to AMBCrypto, if Solana DvP takes off, the bigger story would be institutions using the network to move and settle assets. It would change the paradigm of what institutions are using the Solana network for, from owning Solana [SOL] to using Solana as an infrastructure layer.
Solana’s institutional story is moving on-chain A whale opening a $20 million SOL long after the launch suggests that it is more than just a speculative bet.
The market’s reaction to the news has been quick, with JPMorgan, a roughly $880 billion financial giant, playing a critical role in the design of the system. That itself is a strong signal that TradFi interest in blockchain is shifting from just investing in crypto to using the infrastructure.
At the same time, Circle is continuing to mint USDC on Solana, with another $750 million recently minted.
According to AMBCrypto, this is where Solana’s liquidity shift and the DvP launch start to connect.
Is Solana’s liquidity moving beyond memecoins? As the chart below shows, in Q1 2025, memecoins drove nearly $260 billion in quarterly spot volume. Now, that’s down to around $57 billion.
On the other hand, the tokenized-asset spot volume grew from only $33 million to $8 billion, marking a 242x increase.
Source: Blockworks In short, Solana is seeing its activity shift from memecoin speculation to more utility-oriented markets.
Against this backdrop, the DvP launch could be much more relevant for Solana’s emerging institutional use case. With tokenized assets already on-chain, DvP could enhance this setting by improving transaction finality and overall network efficiency.
Thus, Solana’s institutional adoption is entering a phase of real-world application, diverging and setting up a different type of SOL institutional cycle, one which is driven by actual network utilization and liquidity.
Price Drop Does Not Dent ActivityThe Solana meme coin category fell roughly 6% on October 7, 2026, yet the session told a more complicated story beneath the headline loss. According to CoinGecko data cited by @BSCNews, the category still recorded more than $7.2 billion in 24-hour trading volume, a figure that underscores how much speculative appetite remains even during broad price declines. The category-wide correction brought the total market cap to approximately $3.59 billion, yet high trading volume across top assets held firm.
Among the heaviest traded tokens on the day were solana:2zMMhcVQEXDtdE6vsFS7S7D5oUodfJHE8vd1gnBouauv and solana:6p6xgHyF7AeE6TZkSmFsko444wqoP15icUSqi2jfGiPN, both of which retained meaningful liquidity despite the market-wide pullback. Major assets like PENGU and TRUMP led the volume charts despite significant price retreats across the board.
Pumpfun Token Extends RecoveryThe standout performer in the session context was solana:pumpCmXqMfrsAkQ5r49WcJnRayYRqmXz6ae8H7H9Dfn, the native token of the Pumpfun launchpad, which has gained roughly 60% over the past 30 days from its mid-year lows. PUMP has managed to reverse its 2026 losses and booked a significant gain after a surge in the last 30 days, with the Solana-based launchpad continuing to capture significant volumes as traders return to speculate on meme coins.
Pumpfun reclaimed its launchpad crown and became the first application in Solana's history to cross $1 billion in lifetime revenue, a milestone that has supported sentiment around the token. When launchpad share climbs, buyback capacity climbs with it, because Pumpfun funds its PUMP purchases directly from fee income, and during its last recovery push the platform ran daily buybacks of at least $1 million.
Despite the positive momentum, risks are building. Reports point to rising liquidation pressure as broader meme coin sentiment faces headwinds. Pumpfun faces launchpad competition, volatile meme coin demand, execution risks, and regulatory scrutiny. The token's rally also faces a looming threat from expired vesting schedules for both the development team and existing investors, which could introduce fresh selling pressure if holders choose to exit. Traders watching the space should weigh strong on-chain volume against these structural overhangs before drawing conclusions about the durability of the current bounce.
Sources:
CoinGecko: Solana Meme Coins Category
Yahoo Finance: Pump.fun PUMP Reverses Downtrend After 200-Day EMA Breakout
Phemex: Why PUMP Token Is Rallying as Pumpfun Reclaims Solana
Solana v září zaznamenala více než 8 400 měsíčně aktivních programů, což podle on-chain dat představuje rekord. Měsíční tržby aplikací dosáhly 180 milionů USD.
Solana just had a busy month on the developer side. Data shared on X shows the network’s monthly unique active programs climbed past 8,400 in September, a figure described as a new record.
Programs are Solana’s version of smart contracts: the code behind every swap, bridge, bot and game on the chain.
The numbers behind the build-out Funded wallets on Solana rose 38.5% month-over-month to 16.1 million. A funded wallet holds a balance, which separates it from the abandoned addresses that pad most user counts.
Advertisement
Daily active stablecoin addresses reached 888,000, a 269% increase year-over-year.
Monthly app revenue on Solana reached $180 million in September, a nine-month high. Daily revenue peaked at $7.935 million on September 12.
That $180 million represented 32% of total blockchain app revenue for the month.
Who is actually using all those programs The largest single category was arbitrage and sandwich bots, with 877 active programs. Behind the bots came DeFi applications at 315 programs, bridges at 288, gaming and casino programs at 222, and swap protocols at 168. Standout names included the Pump.fun AMM and Jupiter Aggregator v6.
Not every dashboard counts the same way The headline figure deserves some context. Separate data shared by SolanaFloor put Solana’s September monthly active programs at 7,699, which it described as the highest level since August 2025 rather than an all-time high.
Of roughly 42,500 programs deployed on Solana, only about 3,118 showed sustained user interaction during the period, according to the same research.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
SwissBorg zařadil Worldcoin (WLD), který mohou retailoví i institucionální klienti vkládat, vybírat a směňovat. Platforma je v souladu s nařízením MiCA a čerpá likviditu z více než 45 burz.
SwissBorg Adds $WLD for Retail and Institutional Users@Swissborg has added the @Worldcoin token $WLD to its platform, opening access for both retail and institutional clients. Users can now deposit, withdraw, and swap $WLD alongside more than 400 other digital assets, with one-touch fiat conversions available across 12 countries.
MiCA Compliance and Smart Liquidity RoutingThe listing comes on the back of SwissBorg's full transition to operating under the European Union's Markets in Crypto-Assets (MiCA) framework.
For users, the practical benefit of the $WLD listing lies in how SwissBorg handles execution. The platform's auto-routing system sources liquidity from more than 45 exchanges, removing the need to manage off-platform wallets, bridges, or gas tokens.
The addition of $WLD broadens SwissBorg's catalogue and gives the Worldcoin ecosystem a regulated European distribution channel at a time when MiCA compliance is becoming a baseline requirement for platforms serving EU users.
Sources:
Crypto Briefing: SwissBorg adds Worldcoin's WLD token with multi-asset swaps
CoinDesk: SwissBorg Secures MiCA Approval from France's Financial Markets Authority
SwissBorg Official Blog: SwissBorg Secures MiCA Authorisation for Crypto-Assets in Europe
Osmihodinový čistý příliv na spotovém trhu SHIB vzrostl o 440,65 % na 506 680 USD, krátkodobé toky na spotovém trhu i trhu futures však zůstávají záporné.
Cover image via depositphotos.com Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.
Shiba Inu is recording a major increase in spot-market capital flows, but the more recent data is less reassuring at this point in time. SHIB's eight-hour spot net-flow change has surged 440.65%, producing positive net inflows of approximately $506,680.
Shiba Inu left outThe improvement extends across several longer intraday periods. Four-hour spot net inflows stand at $394,170, up 337.15%, while the 12-hour reading remains positive at $352,220. Over 24 hours, inflows of $6.72 million exceeded $6.11 million in outflows, leaving SHIB with approximately $613,500 in positive net flows.
On the surface, this suggests capital is returning to SHIB. The catch is that shorter-term flows have already started moving in the opposite direction.
HOT Stories
SHIB/USDT Chart by TradingViewOver the latest hour, SHIB recorded $211,140 in spot inflows against $247,370 in outflows, creating a negative net flow of $36,230. The 30-minute reading is similarly negative at $26,830. More importantly, the three-day picture remains negative by approximately $388,160.
Futures flows offer little additional reassurance. Net flows are negative across the five-minute, 15-minute, 30-minute, one-hour, four-hour and 12-hour periods shown, with the 12-hour reading reaching negative $433,240. Only the eight-hour period remains marginally positive.
You Might Also Like
Price action is beginning to reflect this deterioration. SHIB trades around $0.00000550 after a sharp daily decline from the $0.00000580 region. The move has pushed the token back below its long-term moving average near $0.00000565, erasing one of the more important technical improvements from the September recovery.
Market being tested$0.00000540–$0.00000545. Holding this area could allow another attempt to reclaim $0.00000560 and eventually $0.00000580–$0.00000600. A breakdown below $0.00000540 would be considerably more problematic, potentially exposing $0.00000520 and the psychologically important $0.00000500 level.
The 440% increase therefore shows that spot demand strengthened over the longer intraday window. But weakening short-term spot flows, broadly negative futures flows and SHIB's loss of long-term technical support suggest that buyers have not secured control of the market.
SpaceX jedná o financování ve výši 40 miliard USD na nákup čipů Nvidia, včetně přibližně 10 miliard USD v bankovních úvěrech a 30 miliard USD v dluhopisech s investičním ratingem.
SpaceX Corp (NASDAQ:SPCX), Elon Musk’s rocket and artificial intelligence (AI) company, is seeking $40 billion in financing to buy Nvidia chips, potentially creating one of the largest debt-funded AI hardware purchases.
The proposed financing would comprise about $10 billion in bank loans and $30 billion in investment-grade bonds, with Apollo Global Management (NYSE:APO) expected to lead the transaction and Pimco among investors considering the debt.
Bloomberg and the Financial Times reported that talks remain at an early stage, with the financing expected to close in 2027, while SpaceX, Nvidia, Apollo and Pimco have not commented.
The borrowing highlights the capital required to build AI infrastructure, as companies spend heavily on processors, data centers and power equipment.
SpaceX has expanded its computing operations since incorporating xAI, Musk’s AI business, and has said its data centers will use Nvidia hardware exclusively.
Musk said last month that Colossus 2, an AI computing cluster in Tennessee, had 110,000 Nvidia GB200 chips and 440,000 GB300 chips, with as many as 660,000 additional GB300s potentially coming online by December.
The expansion could take Colossus 2 beyond 1.2 million Nvidia chips, underscoring the scale of computing capacity Musk is building to support AI services including Grok.
The financing would extend a trend in which banks and asset managers provide capital for AI hardware rather than requiring technology companies to fund purchases entirely themselves.
Apollo has become a major participant in this market, while Nvidia is working with financial firms on broader financing structures to help customers fund infrastructure needed to deploy its processors.
The proposed deal comes after SpaceX completed an $86 billion initial public offering in June and raised $25 billion through a bond sale, increasing scrutiny of its spending and debt.
Progyny očekává, že smluvní závazky a zbývající rozhodnutí přinesou při spuštění programů v první polovině roku 2027 celkem 1,2 milionu nově pojištěných osob.
Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions
Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI
Progyny’s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed key insights from the Company’s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027.
Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend. Progyny’s solutions are addressing very real and highly prevalent medical needs for women and families, making these categories particularly relevant to today’s workforce.
This season, Progyny is seeing the savviest and most data-intensive employers meet this challenge — whether or not they currently provide coverage for infertility — by leaning into those benefit managers, like Progyny, who have a proven history of mitigating that broader cost trend through programs that drive savings through a combination of superior clinical outcomes and effective total cost management.
“With the commitments we have received to date and anticipated remaining decisions, our selling season is pacing to a potential record level for new lives added for our managed fertility solution,” said Pete Anevski, Chief Executive Officer, Progyny. “We believe it isn’t coincidental that we’re seeing these strong results given the expected record increases in the overall medical plan cost in 2027.”
While buyers continue to be focused on cost, quality, and member experience, there is also a heightened focus on accountability and a proven track record of success. Progyny’s innovative program has demonstrated a consistent ability to increase the effectiveness of fertility treatment while lowering the risk of costly complications, including high-risk pregnancies, miscarriages, and multiple births.
“For those employers actively looking for ways to maintain or expand the family building services they are providing to their workforce in 2027, and who recognize the importance of doing so in a fiscally responsible way, Progyny’s standard practice includes an accelerated contracting path when working through one of our many channel partners and our best-in-class implementation timetable,” concluded Anevski.
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues,” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.
AST SpaceMobile po neúspěšném vypuštění satelitu BlueBird 7 zaznamenala ve 2. čtvrtletí ztrátu 125,9 mil. USD z nucené konverze související s BB7 a již pošesté v řadě nesplnila odhad zisku na akcii (EPS).
A failed satellite launch and six straight earnings misses cut AST SpaceMobile nearly in half, but one Wall Street analyst sees a path back that most investors are overlooking.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AST SpaceMobile (NASDAQ:ASTS) is changing hands at $63.12. The consensus analyst price target is $77.94, which puts the stock 23.5% below where analysts on average think it should be.
AST SpaceMobile is building a space-based cellular broadband network connecting BlueBird satellites directly to smartphones. It has over 60 mobile network operator partners covering over 3 billion subscribers and growing U.S. government contracts.
Roth MKM reiterated a Buy rating with a $108.00 target, indicating 71.1% upside. The stock sits 52.8% below its 52-week high of $133.86.
A Failed Launch and Six Straight Misses Cut the Stock in Half A Blue Origin rocket left the BlueBird 7 satellite in too low an orbit. Shares dropped 15% on the news, and the company recorded a $125.9M loss on involuntary conversion tied to BB7 in Q2.
Q1 revenue came in at $14.73M, missing the $36.58M consensus by 59.72%. Q2 revenue of $31.52M also missed, and GAAP EPS of -$0.77 fell short of the -$0.29 estimate. This marks 6 consecutive EPS misses. An $88.7M induced conversion expense on convertible notes kept dilution concerns alive.
The selloff was specific to AST SpaceMobile. Satellite rivals rallied, and talk of a SpaceX IPO added competition concerns from Starlink.
Roth MKM’s $108 Case Rides on a 45-Satellite Constellation Roth’s thesis: the BlueBird architecture gives AST SpaceMobile a multi-year lead over Starlink; deals with tier-1 carriers provide access to billions of subscribers without retail customer acquisition; and margins widen as launches convert the partner pipeline into revenue.
Key points: a backlog of roughly $1.3 billion, 2026 revenue guidance of $150 to $200 million weighted toward Q4, and a target of about 45 satellites in orbit by early 2027. Management expects commercial service to begin at that count and aims for close to $1 billion in revenue in the first full year of service. It has 10 launches recorded with two providers.
Funding covers near-term needs. Pro forma cash tops $3.7 billion after a $1.15 billion convertible offering at 1.625%. Three new government awards carry over $100 million in funded near-term value, and Japan’s J-LEO project could be worth up to roughly $1 billion, pending approvals. The company’s president put it simply: “Our deployment roadmap remains on track.”
Of the 14 analysts covering the stock:
Strong Buy: 1 Buy: 4 Hold: 7 Sell: 1 Strong Sell: 1 Deutsche Bank lowered its target from above $130 to $106.00. Price targets are estimates.
Satellite Rivals Rallied on Takeovers While AST SpaceMobile Slid AST SpaceMobile fell on its own. Its closest public peers became acquisition targets.
Iridium Communications (NASDAQ:IRDM | IRDM Price Prediction) is up 185.7% year to date following Rocket Lab‘s (NASDAQ:RKLB) $8 billion deal to buy it. At $49.04, it trades above its $42 average target, which indicating 14.4% downside. Analysts lean positive, with 1 Strong Buy, 3 Buys and 4 Holds, but their targets have not kept up with the price.
Globalstar (NASDAQ:GSAT) is up 37.01% year to date at $83.63. Its $90 target, which indicating 7.6% upside, matches Amazon‘s (NASDAQ:AMZN) $90 per share offer. Analysts rate it 2 Buys and 1 Hold.
AST SpaceMobile has the largest analyst-implied upside in the group. Its peers’ targets are tied to deal prices. AST remains independent, so its price depends entirely on execution.
A Double-Digit Slide During a Strong Year for Stocks At $63.12, shares sit 23.5% below the $77.94 consensus from 14 analysts. The stock is down 13.09% year to date, while the S&P 500 is up 14.26%.
Shares have started to move higher recently. They gained 6.26% over the past week, including 8.01% in the latest session. The price still sits below the 200-day moving average of $81.09. With a beta of 2.706 and a price-to-sales ratio of 197, expect large swings in either direction.
Execution Will Decide Whether $108 Is Realistic The optimistic scenario strengthens if launches resume on schedule, the constellation reaches about 45 satellites by early 2027, and Q4 revenue drives the company into its guidance range. The bear case gains weight if another launch fails, Q4-weighted revenue slips into 2027, or carrier partnerships stall before reaching commercial service.
With over $3.7 billion in cash, execution is the primary risk. The $77.94 consensus is the realistic near-term target. Roth’s $108 needs launch results that have not yet happened.
Contact [email protected] for any questions or corrections.
Allient ve 2. čtvrtletí zvýšil objednávky o 49 % na rekordních 201,3 milionu USD, přičemž tržby z datových center a infrastruktury vzrostly o 60 % na 16,3 milionu USD.
This is a fair market value price provided by Massive. Learn more.
$42.42▼
$121.420.14%
66.87
$84.00
Allient Inc. NASDAQ: ALNT has long been the kind of company only an engineer would love.
The manufacturer, formerly known as Allied Motion Technologies, makes precision motors, drives, controls, and power-quality equipment that are hidden inside factory robots, surgical tools, military systems, and powersports vehicles.
Get Allient alerts:
Engineers are not its only fans anymore. Allient has become a player in three of the hottest themes in the market today: data center power, defense, and drones.
The challenge for Allient these days is that the stock has run past almost every analyst's price target. For investors, the question is whether the business is changing faster than Wall Street's models, or the stock has gotten ahead of itself.
Earnings Growth Sets a High BarAllient's second-quarter report on Aug. 5 set a high bar for its next earnings release, which is expected in early November. Revenue climbed 10% to $153.8 million, or 9% on an organic, constant-currency basis, topping the $145.7 million analysts expected. The stock jumped about 19% the next trading day.
Profits grew even faster than sales. Gross margin hit a record 34.9%, up 1.7 percentage points, and operating margin rose to 10.2% from 8.4%.
Net income jumped 85% to $10.4 million, or 61 cents per diluted share, versus 34 cents a year earlier. Adjusted earnings came in at 80 cents per share, well ahead of the 61-cent analyst consensus.
That makes the upcoming report an important test of whether the surge in orders, margin improvement, and data center demand carried into the second half of the year.
Record Orders Are the Bigger StoryThe real headline in the report, though, was demand. Orders surged 49% to a record $201.3 million, giving Allient a book-to-bill ratio of 1.31, meaning it booked $1.31 in new business for every dollar it shipped. Backlog swelled to $298 million, most of which management expects to turn into revenue within three to nine months.
The growth is coming from the right places. Industrial sales rose 17%, aerospace and defense rose 16%, and medical rose 9%. The vehicle market fell 7%, however, due to weak powersports demand. Sales tied to data centers and infrastructure reached $16.3 million, or 10.6% of revenue, up 60% from a year earlier.
AI Infrastructure and Defense Are Becoming Bigger Growth EnginesIn short, Allient has repositioned itself in markets that are growing faster than its old ones. In data centers, its Allient Power unit sells harmonic filters and related gear that keep the electricity feeding AI servers clean and stable.
Management says it has the highest-power active filter on the market and is finishing a capacity expansion due online late in the third quarter or early in the fourth.
Defense is the second engine. On Aug. 5, Allient launched a new propulsion controller designed to meet National Defense Authorization Act supply-chain rules for military drones. Then on Sept. 29, the company announced it had earned Cybersecurity Maturity Model Certification Level 2, which is valid for three years and strengthens its ability to compete for defense work involving sensitive information.
For investors who want growth stocks with real profits rather than promises, that’s an appealing mix. Income investors won’t be too impressed, though, even as the board raised the quarterly dividend payout 33% to 4 cents per share in May, a yield of only about 0.14%.
Analyst Targets Haven’t Kept Up With the RallyAllient Stock Forecast Today12-Month Stock Price Forecast:
$84.00
-28.35% Downside
Buy
Based on 6 Analyst Ratings
Current Price$117.24High Forecast$120.00Average Forecast$84.00Low Forecast$70.00Allient Stock Forecast Details
Analysts are clearly supportive. With one Strong Buy rating, four Buy ratings, and a Hold, the consensus rating for Allient is a Buy.
Several analysts, however, have yet to issue new targets for the company, with many still carrying an $80 level set earlier this year, which apparently does not account for a nearly 35% rise in the stock price over the past three months.
Because of that, the 12-month consensus target price remains at $84, about 29% lower than its current trading price.
The most recent adjustment was from JPMorgan Chase NYSE: JPM, which boosted its target two days after recent earnings to $120 per share.
Since the start of the year, Allient shares are up more than 120%.
A Higher Valuation Leaves Less Room for MistakesGiven the unknown duration of the boom that’s occurring in several of its important sectors, valuation is likely the most important risk. At roughly 43 times this year's expected earnings, Allient is priced like a high-growth tech company, not a maker of motors and filters growing sales at high single digits. Any slowdown in orders could hit the shares hard.
There are potentially also some quality-of-earnings questions. Management acknowledged that longer supply-chain lead times are pulling some customer orders forward by about three months, and operating cash flow fell to $20.1 million in the first half from $38.4 million a year earlier, as the company built inventory and waited on receivables.
There is also competition. AMETEK NYSE: AME and Parker-Hannifin NYSE: PH, among others, also fight in this space.
The Next Earnings Report Could Be the Real TestThe reality is that Allient is a more attractive company these days. Margins are at records, debt is falling, orders are piling up, and the company is well-positioned in data centers and defense.
Right now, the company does not appear as a true value stock, and at these levels, investors are paying up for future execution. That puts more weight on Allient's upcoming third-quarter report, when investors will get a fresh look at whether record order activity is translating into revenue, margins are holding near recent highs, and cash flow is beginning to catch up with earnings growth.
If those come in strong, for investors who want to buy stocks with exposure to AI infrastructure and defense spending, Allient provides an appeal that now goes well beyond the world of engineers.
Should You Invest $1,000 in Allient Right Now?Before you consider Allient, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allient wasn't on the list.
While Allient currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Společnost SpaceX Elona Muska jedná s bankami a investory o financování až ve výši 40 miliard dolarů, které by měly podpořit masivní rozšiřování její infrastruktury pro umělou inteligenci. Prostředky mají sloužit především k nákupu čipů Nvidia pro datová centra, čímž se firma zařazuje mezi technologické giganty investující desítky miliard dolarů do AI.
Vesmírná společnost SpaceX nejbohatšího člověka světa Elona Muska jedná s bankami a investory o půjčkách až 40 miliard dolarů (zhruba 872 miliard Kč) na nákup čipů od americké společnosti Nvidia. Informovala o tom agentura Bloomberg s odvoláním na informované zdroje.
SpaceX plánuje získat přibližně deset miliard dolarů v bankovních úvěrech a dalších 30 miliard dolarů prostřednictvím půjček od investorů. Na financování se podle zdrojů Bloombergu podílí investiční společnost Pacific Investment Management (Pimco), zatímco podle dřívějších informací listu Financial Times transakci vede Apollo Global Management. Uzavření dohody se očekává v roce 2027.
Peníze mají financovat rozvoj infrastruktury pro umělou inteligenci (AI). Firmy z technologického sektoru a vývojáři modelů AI v současnosti půjčují stovky miliard dolarů na budování a pronájem rozsáhlých datových center vybavených čipy pro provoz systémů AI. Rostoucí poptávka zdražuje pozemky, čipy a zařízení pro výrobu elektřiny, připomněl Bloomberg.
Musk minulý měsíc uvedl, že výpočetní centrum Colossus 2 jeho firmy xAI v Memphisu může do konce roku více než zdvojnásobit počet čipů Nvidia. Centrum má nyní 110.000 čipů GB200 a 440.000 GB300, přičemž další dodávky mají počet dále zvýšit. Apollo již dříve poskytlo xAI financování sedmi miliard dolarů na přístup k čipům Nvidia.
Společnost SpaceX zabývající se vesmírnými raketami či AI vstoupila 12. června na burzu po rekordní primární nabídce akcií (IPO). Ta jí vynesla 85,7 miliardy dolarů. SpaceX před vstupem na burzu uvedla, že v roce 2025 vykázala ztrátu 4,9 miliardy dolarů. Ztrátová divize zaměřená na AI vynaložila 12,7 miliardy dolarů na kapitálové investice. Začátkem letošního roku se firma SpaceX spojila s Muskovým start-upem xAI zaměřeným na AI. Hlavním zdrojem tržeb SpaceX loni byla satelitní služba Starlink.
Herní hub Flux nyní hostuje 15 herních titulů; herní servery představují 865 z celkem 1 913 aplikací v síti. RuneScape: Dragonwilds vede se 484 instancemi.
Fluxers! A month ago we wrote about ten games in one hub. The Flux games hub now hosts fifteen — and in that month it has become one of the biggest engines of growth on the whole network.
When we re-ran the network census for Flux in Numbers, 865 of the 1,913 applications on Flux were game servers — 45% of everything registered. Here is what is new, and the full lineup.
Five new worlds V Rising — from $6.99 a month. Gothic vampire survival, where your castle stays standing when you log off. Satisfactory — from $4.99 a month. Your factory keeps running for the whole group, not just whoever happens to be hosting. 7 Days to Die — from $5.99 a month. Build, scavenge and survive the horde nights together. ARK: Survival Ascended — from $11.99 a month. Tame, build and survive on a server sized for it. Hytale — from $2.99 a month, the newest arrival. The breakout: Dragonwilds RuneScape: Dragonwilds joined the hub just before its 1.0 release, and it has become the most deployed game we host — 484 servers at the last census, more than every other title on the hub combined. From $5.49 a month, with every plan running the full six-player world. We wrote up what hosting it taught us.
The full lineup Fifteen games, every one with its own page, its own plans sized to what that game actually needs, and a starting price you can see before you sign up:
Terraria — from $1.49 Minecraft — from $1.99 Hytale — from $2.99 Palworld — from $3.49 Enshrouded — from $3.49 Valheim — from $4.99 Satisfactory — from $4.99 Windrose — from $4.99 Project Zomboid — from $4.99 RuneScape: Dragonwilds — from $5.49 7 Days to Die — from $5.99 V Rising — from $6.99 Rust — from $7.49 ARK: Survival Ascended — from $11.99 FiveM — from $12.49 All prices are monthly.
Your first week is free If you are new to Flux Cloud, your first week is free. Pick a game, pick a plan, and play — there is no reason to guess whether a server is right for your group before you have tried it.
What makes a Flux game server different Your world does not have to live on one machine. Servers for games such as Dragonwilds, ARK and Hytale keep your world synced to a standby node — one copy live, one ready on a separate machine. If the node under your world goes away, the standby takes over with your world already on it. We explained exactly how in One Live, One Standing By.
You choose where it runs. Latency is the whole experience in a multiplayer game, and Flux runs across thousands of independently operated machines around the world. The hub has a locations page so you can put your server near your players.
Your settings stay private. The hub deploys every server privately, so passwords and server settings are encrypted and never appear on chain. Only nodes running ArcaneOS, which prove what they are, can run them.
Nobody can quietly take it away. Every server is an application registered on chain and hosted by operators with collateral at stake. There is no account review to fail and no single company in the middle.
Pick your world Everything is at runonflux.com/games. Choose a game, choose a location, and your server is running in minutes — with a week on us if it is your first.
Akcie D-Wave Quantum letos klesly o 39,62 % poté, co společnost ve druhém čtvrtletí vykázala tržby ve výši 3,08 mil. USD, což bylo o 23,63 % méně, než činily odhady.
D-Wave quantum stock sits nearly 40% in the red while one Wall Street analyst holds a price target that would triple your money. The catch is a single quarter that could either validate the bull case or expose a very…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
D-Wave Quantum (NYSE:QBTS) is trading at $15.79. The consensus price target sits at $34.65, which means about 119% upside.
D-Wave is the only quantum computing company pursuing both annealing and gate-model systems. It runs production workloads for customers such as AT&T (NYSE:T | T Price Prediction) and Optum. In January 2026, it acquired Quantum Circuits to add gate-model capability.
The most bullish call on the stock comes from Rosenblatt Securities analyst John McPeake, who holds the Street-high $43.00 target. That target means about 172% upside from here.
A Revenue Miss and Rising Costs Pushed D-Wave Down Nearly 40% Second-quarter revenue of $3.08M came in 23.63% below the $4.03M consensus and was about flat year over year. GAAP EPS of -$0.13 missed the -$0.0914 estimate.
Operating expenses nearly doubled to $54.98M, and adjusted EBITDA loss grew 85% to $37.1M. Cash and investments fell to $546.2M from $819.3M, with more than 90% of that drop due to the about $250 million cash payment for Quantum Circuits. Share count grew from 266.6M to 358.7M during fiscal 2025.
The stock is down 39.62% year to date and 66% below its 52-week high of $46.75. Other quantum stocks fell too, but D-Wave has the worst year-to-date loss in the group.
Rosenblatt’s $43 Call Rests on Annealing Already Earning Revenue Of the 17 analysts tracked, 1 rates it Strong Buy, 15 rate it Buy and 1 rates it Hold. None rate it Sell. Rosenblatt reiterated its Buy rating despite the miss.
Rosenblatt’s view: D-Wave leads in commercial annealing systems that solve optimization problems today. Leap should generate high-margin recurring cloud revenue as customers move from pilot programs into production. Hybrid quantum-classical solvers deliver value now, so customers don’t wait for fault-tolerant machines.
First-half bookings reached $35.5M versus $2.9M a year earlier. Remaining performance obligations rose 668% to $40.7M, with about 57% recognized within 12 months. D-Wave has six customer applications in production.
Management expects third-quarter revenue to be “up modestly” and fourth-quarter revenue to be “up significantly,” with two annealing systems likely shipping in the fourth quarter. D-Wave doesn’t expect significant gate-model cloud revenue until 2032. Price targets are not guarantees, and this one depends on annealing doing the heavy work for years.
Quantum Stocks Fell Together, and D-Wave Fell Hardest Every stock in the peer group sold off. D-Wave’s decline was sharper than its peers’.
IonQ (NYSE:IONQ) is down 3.52% year to date at $43.33. Its average target of $66.63 means about 54% upside. Analysts rate it 1 Strong Buy, 11 Buy, 2 Hold.
Rigetti Computing (NASDAQ:RGTI) is down 31.51% year to date at $15.17. Its target of $28.52 means about 88% upside. Ratings: 1 Strong Buy, 8 Buy, 4 Hold.
Quantum Computing Inc. (NASDAQ:QUBT) is down 23.39% year to date at $7.86. Its target of $18.67 means about 138% upside. Six analysts cover it (4 Buy, 2 Hold).
Quantum Computing Inc. has the largest consensus upside on paper. D-Wave ranks second and has the widest and most bullish analyst coverage in the group.
D-Wave Is Down 39% While the S&P 500 Rises D-Wave trades at $15.79, less than halfway to its $34.65 consensus target. The stock is down 39.62% year to date, while the S&P 500 is up 14.25%.
Shares have fallen 4.76% over the past month and trade below the 50-day average of $18.14 and 200-day average of $20.80. On trailing revenue of $12.425M, the stock trades at a price-to-sales ratio of 481.83.
D-Wave’s Fourth-Quarter Deliveries Will Test the 172% Call The case for the stock gets stronger if both annealing systems ship in the fourth quarter, the backlog turns into revenue on schedule and Leap’s production customers like Optum and AT&T expand their work. That path could close much of the gap to the consensus target.
The bear case gains weight if fourth-quarter deliveries slip into 2027, spending keeps outpacing revenue and D-Wave issues more shares to fund a gate-model program that won’t produce significant revenue until 2032. In that case, today’s low price would be a value trap.
The production customers and backlog are real, and analysts are almost unanimously positive. The fourth quarter has to deliver before Rosenblatt’s $43.00 target looks realistic.
Contact [email protected] for any questions or corrections.
OneMedNet uzavřel svou 11. partnerskou dohodu se společností Mediplexus, která bude v Koreji distribuovat zdravotnická data společnosti z USA a rozšíří její dosah v asijsko-pacifickém regionu.
MINNEAPOLIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced its 11th channel partner agreement with Mediplexus, a healthcare data company specializing in RWD and Real World Evidence (RWE) and a subsidiary of C&R Research, one of Korea’s leading contract research organizations (CROs). Under the agreement, OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, its appointed distributor in Korea – extending OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the scope of the collaboration in stages following an initial one-year engagement.
Through the agreement, Mediplexus will offer OneMedNet’s U.S sourced healthcare data alongside its own Korean healthcare data, each delivered in a form tailored to the customer’s purpose — significantly widening the field on which Korean biopharma, medtech and medical AI companies can pursue global clinical trials, RWD and RWE research, drug development, and medical AI initiatives. Mediplexus plans to pair OneMedNet’s data with analysis, model validation, and regulatory and market-access support to help Korean medical device and medical AI companies enter the U.S. market.
OneMedNet’s iRWD™ network — now exceeding 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites — delivers multimodal data spanning radiology, cardiology, EEG, and ECG, together with de-identified electronic health records. The data is sourced directly from healthcare providers, not intermediaries or secondary markets, and de-identified at the source.
The agreement comes as the global regulatory environment increasingly moves toward formal acceptance of RWD and RWE. Both the U.S. FDA and the European EMA encourage the use of RWE, and following the adoption of the ICH M14 guideline1 in 2025, the global RWE solutions market is projected to grow from USD 5.4 billion in 2025 to USD 10.8 billion by 20302.
“Asia Pacific is expected to register the fastest growth in the RWE solutions market, driven by expanding healthcare data infrastructure2” said Aaron Green, President & CEO of OneMedNet. “This agreement puts our first-party, direct-from-source multimodal data into the hands of a partner with deep clinical research roots in the region. Mediplexus and C&R Research bring the local expertise, relationships, and regulatory know-how to make our data actionable for Korean innovators and this initial engagement is structured to expand in both scope and geography over time.”
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the planned expansion to the Asia Pacific market and related expectations, projected market growth, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
Toronto Dominion Bank (The) (NYSE:TD – Get Free Report) (TSE:TD) announced a quarterly dividend on Thursday, August 27th. Shareholders of record on Friday, October 9th will be given a dividend of C$1.12 per share by the bank on Saturday, October 31st. This represents a $4.48 annualized dividend and a yield of 3.8%. The ex-dividend date is Friday, October 9th.
Toronto Dominion Bank has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 12 consecutive years. Toronto Dominion Bank has a payout ratio of 52.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Toronto Dominion Bank to earn $7.67 per share next year, which means the company should continue to be able to cover its $3.23 annual dividend with an expected future payout ratio of 42.1%.
Toronto Dominion Bank Stock Up 1.0% TD opened at $118.22 on Wednesday. The company has a market cap of $194.45 billion, a P/E ratio of 17.57, a P/E/G ratio of 1.16 and a beta of 0.75. The business’s 50-day moving average price is $120.42 and its 200-day moving average price is $113.90. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.09. Toronto Dominion Bank has a 12 month low of $77.95 and a 12 month high of $125.46.
Toronto Dominion Bank (NYSE:TD – Get Free Report) (TSE:TD) last issued its earnings results on Thursday, August 27th. The bank reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.24. Toronto Dominion Bank had a return on equity of 14.88% and a net margin of 14.41%.The company had revenue of $12.07 billion during the quarter, compared to analysts’ expectations of $10.70 billion. During the same period in the prior year, the business posted $2.20 EPS. Toronto Dominion Bank’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, equities analysts expect that Toronto Dominion Bank will post 7.04 EPS for the current year. Institutional Trading of Toronto Dominion Bank A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cornerstone Financial Management LLC raised its holdings in Toronto Dominion Bank by 77.2% in the 2nd quarter. Cornerstone Financial Management LLC now owns 218 shares of the bank’s stock worth $26,000 after purchasing an additional 95 shares in the last quarter. Bayban purchased a new position in shares of Toronto Dominion Bank during the fourth quarter valued at about $28,000. Brown Lisle Cummings Inc. increased its position in shares of Toronto Dominion Bank by 88.4% during the first quarter. Brown Lisle Cummings Inc. now owns 407 shares of the bank’s stock valued at $38,000 after buying an additional 191 shares during the period. Continuum Advisory LLC bought a new position in Toronto Dominion Bank in the second quarter worth about $43,000. Finally, NBH Bank purchased a new stake in Toronto Dominion Bank in the second quarter worth about $73,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.
Toronto Dominion Bank Company Profile (Get Free Report)
Toronto-Dominion Bank, operating as TD Bank Group, is a Canadian financial services company headquartered in Toronto, Ontario. The bank was formed in 1955 through the merger of The Bank of Toronto and The Dominion Bank and serves customers in Canada and the United States.
TD provides a broad range of banking and financial services, including personal and commercial deposit accounts, lending, mortgages, credit cards, payments, investment products and financial advice. Its Canadian operations serve individuals, businesses and institutions, while its U.S.
Further Reading Five stocks we like better than Toronto Dominion Bank Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Toronto Dominion Bank Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Toronto Dominion Bank and related companies with MarketBeat.com's FREE daily email newsletter.
Společnost ČEZ, a.s. zveřejňuje zprávu o prodeji podílu ve slovenské společnosti JESS.
Více informací zde.
(komerční sdělení)
Tagy: Povinně uveřejňované informace
Reklama
Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.
Aktuální komentáře
07.10.2026 15:06Porsche mění kurz. Chce prodávat méně aut, ale za vyšší ceny 15:01ČEZ, a.s.: ČEZ prodává podíl ve slovenské společnosti JESS 13:40Siegel: Vyšší sazby snižují relativní atraktivitu akciového trhu a zejména jeho část mimo technologie 12:06Krugman: JPMorgan a předzvěst velkého posunu v USA 11:54Írán a vyšší výnosy zabrzdily akcie v rozletu. Evropské trhy ztrácejí 10:48Evercore ISI: Tento spotřebitelský gigant se vrací do formy a má prostor k růstu 9:00Rozbřesk: Jádrová inflace nad 3 % a slabá koruna nahrávají dalšímu utažení měnové politiky. 8:50Evropské akcie zamíří níže, vyjdou česká data z průmyslu a stavebnictví 6:08Umělá inteligence má znatelný vliv na pracovní místa, ten ale maskují agregovaná čísla 06.10.2026 22:05Akcie na Wall Street se obchodovaly u maxim, Nvidia se blíží hranici 6 bilionů dolarů 17:28Výrazný pokles valuací maskuje to, jak investoři na akciích stále smýšlí 15:48Zrodil se nový mediální obr. Skydance dokončila převzetí Warner Bros. Discovery 15:27Nvidia míří k hranici šesti bilionů dolarů. Investory láká růst i valuace 13:52Ray Dalio varuje: Čína a Japonsko couvají. Americkému dluhu hrozí problémy 12:37SpaceX se vrací do kurzu. Wall Street znovu objevuje její potenciál 11:15Růst akcií se přesouvá do Evropy s podporou levnější ropy a zklidnění francouzských dluhopisů 10:59Jak si vsadit na americké volby? JPMorgan ukazuje možné vítěze na burze 10:15DOORNITE míří na burzu: Webinář s CEO Pavlem Šatným o firmě, plánech růstu i detailech IPO 9:52Meziroční inflace v září zrychlila na 2,5 procenta ze srpnových 1,9 procenta 9:08Rozbřesk: Opětovná polská intervence proti „drahé naftě“ zřejmě zabrání zvyšování sazeb NBP
Reklama
Související komentáře
Nejčtenější zprávy dne
Nejčtenější zprávy týdne
Nejdiskutovanější zprávy týdne
Kalendář událostí
ČasUdálost PL - Jednání NBP, základní sazba 8:00DE - Průmyslová výroba, y/y 9:00CZ - Obchodní bilance - nár. pojetí, mld. Kč 9:00CZ - Průmyslová výroba, y/y 20:00USA - Zápis z jednání FOMC
Potřebujte poradit?
Porsche chce snížit náklady a soustředit se na nejluxusnější vozy. Ziskovosti chce dosahovat i při ročním prodeji méně než 200 000 vozů, oproti loňským 279 449 vozům.
Automobilka Porsche představila novou strategii, která počítá s výrazným snižováním nákladů a větším důrazem na nejluxusnější modely. Německý výrobce sportovních vozů chce v budoucnu prodávat méně aut, ale za vyšší ceny, a zajistit si tak vysokou ziskovost i v době, kdy evropský automobilový průmysl čelí rostoucím nákladům, čínské konkurenci a americkým clům.
Německý výrobce luxusních sportovních vozů Porsche plánuje v příštích letech výrazně snížit náklady. Firma v dnešní tiskové zprávě o nové strategii rovněž uvedla, že hodlá klást menší důraz na objem prodeje a že se zaměří na nabídku automobilů nejvyšší třídy. Chce tak v budoucnosti prodávat méně vozů, ale za vyšší ceny, napsala agentura AFP.
"Naše strategie položí základy ke zvýšení efektivity, produktivity a ziskovosti Porsche," uvedl šéf podniku Michael Leiters. "Nyní se soustředíme zejména na snižování nákladů a posílení finanční pozice podniku," dodal.
Automobilka Porsche chce v rámci nové strategie zajistit, aby dosahovala ziskovosti i při objemu prodeje pod 200.000 vozů ročně. V loňském roce přitom dodala zákazníkům 279.449 vozů.
Německý automobilový průmysl se v poslední době potýká s řadou problémů, včetně vysokých nákladů, nadbytečných kapacit, rostoucí čínské konkurence nebo amerických cel.
Automobilka Porsche v roce 2022 vstoupila na frankfurtskou akciovou burzu. Jejím většinovým vlastníkem nicméně zůstal německý automobilový koncern Volkswagen, jehož součástí je také Škoda Auto.
Dozorčí rada koncernu Volkswagen minulý měsíc schválila největší restrukturalizační plán v historii podniku, který zahrnuje rozsáhlé rušení pracovních míst a omezení počtu modelů. Škoda Auto opakovaně uvedla, že nový transformační plán koncernu nemá na její aktivity žádný přímý dopad.
Automobilka Porsche byla dlouhou dobu spolehlivým zdrojem zisků koncernu Volkswagen. V současnosti je však podle analytiků pro koncern spíše přítěží a dostává se do stínu Škody Auto. "Česká značka se fakticky stává novým Porsche celé skupiny," uvedl minulý měsíc nezávislý analytik automobilového průmyslu Matthias Schmidt.
Event Passes are mini Battle Passes that last shorter but happen much more often. Which Rangers can claim all their exclusive rewards? Not only that, but each Event Pass ends with a spectacular Premium-only tournament.
Next up is the Abyssal Chasm Event Pass: queue Ranked Gauntlet, earn Arena Points, and claim Illuvials, Fuel, XP boosts, an emote, and the Abyssal Chasm Challenger title.
This Event Pass is built around Abyssal Chasm and the Illuvials that hunt there. Play it out on two tracks: a Free Track for every Ranger, and a Premium Track including bigger Fuel Drops, more powerful XP boosts, but most importantly: more powerful Illuvials.
Start: 7th October 2026
End: 27th October 2026, 00:00 UTC
Duration: 19 days
Premium: 800 Fuel
There’s also Illuvium Challengers Series #2 hosted by Sylen, Premium Event Pass required, $500 USD in ILV. Full tournament details are at the end.
Open Event Pass in the Arena client.
Only Ranked Gauntlet matches grant Arena Points and count toward missions.Claim rewards as you hit each Arena Point threshold (3 → 750).Everyone can progress the Free Track.Unlock Premium for 800 Fuel to claim the Premium Track and Premium Missions.The Event Pass runs for 19 days. Finish what you start: once the event is over, the rewards are gone as well.
Missions sit on the Event Pass screen and pay extra Arena Points on top of Ranked play.
Each mission is randomly assigned from the mission pool. A mission will not repeat until you have completed every mission in that pool at least once.
Free Missions
Mission
Arena Points
Daily
5
Weekly
20
Examples: get a 10-round win streak in a Ranked match (daily), and play 15 Ranked matches (weekly).
Premium Missions (Premium Event Pass)
Mission
Arena Points
Daily
10
Weekly
40
Examples: hit synergy 5+ in a Ranked round (daily), and activate Invoker and Steam at 3+ at the same time in a Ranked round (weekly).
Illuvials on the tracks come with a set TPI (Trait Purity Indicator) and level. That is Leviathan-ready power, not a cosmetic sticker. Kickstart your way to dominating Illuvium Arena Ranked by owning and improving your collection.
Fuel Drops pay Fuel straight into your account.
XP Boosts on Premium accelerate Illuvial levelling for a fixed window (3 / 7 / 10 / 60 days).
The exclusive emote and the Abyssal Chasm Challenger title are for flexing. Keep using them in Gauntlet to show off your achievements to your opponents.
— = no Free reward at that step. Premium still pays.
Arena Points
Free Track
Premium Track
3
Earth Doka · Stage 1 · 0 TPI · Level 10
Lesser Monkier · 40 TPI · Level 20
5
Water Fliish · Stage 1 · 10 TPI · Level 20
Emote: All In Stoic Floralynx
10
—
50 Fuel Drop
15
Earth Volante · Stage 2 · 20 TPI · Level 30
Lura · 40 TPI · Level 30
25
—
50 Fuel Drop
35
Water Volante · Stage 3 · 25 TPI · Level 45
80% XP Boost · 3 days
50
—
Exalted Monkier · 50 TPI · Level 42
75
Greater Monkier · 30 TPI · Level 30
Exalted Aapon · 50 TPI · Level 42
100
—
100 Fuel Drop
150
25 Fuel Drop
Exalted Grilla · 50 TPI · Level 42
200
—
120% XP Boost · 7 days
250
Loulura · 40 TPI · Level 30
Phorus · 65 TPI · Level 45
300
—
160% XP Boost · 10 days
400
Malura · 45 TPI · Level 45
Goliant · 65 TPI · Level 45
500
25 Fuel Drop
Title: Abyssal Chasm Challenger
750
—
40% XP Boost · 60 days
Nine payouts: starter Earth Doka, Water Fliish, Stage 2 Earth Volante, Stage 3 Water Volante, Greater Monkier, Loulura, Malura (Level 45), and 50 Fuel across two Drops.
Sixteen payouts, including:
Early Lesser Monkier (40 TPI) and the Lynx Nature Bulwark Stage 3 — All In emote200 Fuel in Drops (50 + 50 + 100)Lura at 40 TPI, then Exalted Monkier, Exalted Aapon, and Exalted Grilla at 50 TPIPhorus and Goliant at 65 TPI, Level 45XP: 80% / 3 days, 120% / 7 days, 160% / 10 days, 40% / 60 daysTitle: Abyssal Chasm ChallengerPremium is undoubtedly where it's at for this Event Pass. The Free Track still pays real Illuvials and Fuel. Premium is where TPI, XP boosts, the emote, and the title live.
Update Illuvium Arena on the Epic Games Store and open Event Pass.Queue Ranked Gauntlet: unranked matches do not award Arena Points or mission progress.Clear the assigned Daily and Weekly missions as they come up.Claim on the track as the bar hits 3, 5, 10, 15… 750.Unlock Premium from the Event Pass screen for 800 Fuel if you want the second track and Premium Missions.See you in the Arena, Rangers. Abyssal Chasm doesn’t wait.
The Event Pass is not only a track. Sylen is hosting Illuvium Challengers Series #2 — Ranked Gauntlet, two days, $500 USD in ILV.
Day One: October 18, 2026 · 7:00 PM UTC
Finals: October 25, 2026 · 7:00 PM UTC
Signup sheet: https://forms.gle/cLmfkfdXyng7zoup9
Signup is first come, first served, with a backup list. You need the Premium Event Pass (800 Fuel) to enter. The signup sheet is posted with this announcement.
Day One: October 18
BO1 32 → 16, then BO1 16 → 8.
Finals: October 25
BO3 Points for the remaining eight.
Universal Corporation (NYSE:UVV – Get Free Report) declared a quarterly dividend on Wednesday, August 5th. Stockholders of record on Monday, October 12th will be given a dividend of $0.83 per share on Monday, November 2nd. This represents a $3.32 dividend on an annualized basis and a dividend yield of 7.8%. The ex-dividend date is Friday, October 9th.
Universal has increased its dividend by an average of 0.0%annually over the last three years and has increased its dividend annually for the last 56 consecutive years.
Universal Price Performance Shares of Universal stock opened at $42.67 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.00 and a current ratio of 2.57. The firm’s 50-day simple moving average is $45.80 and its 200-day simple moving average is $50.42. Universal has a twelve month low of $41.10 and a twelve month high of $59.38. The firm has a market cap of $1.06 billion, a P/E ratio of 55.42, a price-to-earnings-growth ratio of 13.25 and a beta of 0.58.
Universal (NYSE:UVV – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.43). Universal had a return on equity of 3.50% and a net margin of 0.67%.The business had revenue of $523.78 million during the quarter, compared to analyst estimates of $587.00 million. As a group, research analysts expect that Universal will post 3.18 EPS for the current fiscal year. Universal Company Profile (Get Free Report)
Universal Corporation (NYSE: UVV) is a global leaf tobacco supplier and processor. Through its operating companies, the company purchases tobacco from growers, processes and blends leaf, and supplies tobacco products and related materials to manufacturers of cigarettes, cigars, pipe tobacco and other tobacco products. Its services include crop contracting, agricultural support, curing, processing, storage, packaging and logistics.
Founded in 1918 and headquartered in Richmond, Virginia, Universal has developed an international network of tobacco sourcing, processing and distribution operations.
Further Reading Five stocks we like better than Universal Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Universal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universal and related companies with MarketBeat.com's FREE daily email newsletter.
For most of its history, Space Exploration Technologies (SPCX +0.48%) was synonymous with rockets. That description is starting to look outdated. Following its initial public offering (IPO) in June, SpaceX gives investors exposure to several markets at once: commercial space launches, government contracts, Starlink, artificial intelligence (AI) infrastructure, and perhaps even space-based computing.
With SpaceX expected to report its next quarterly earnings in early November, investors have a decision to make: Is October a good time to buy SpaceX stock, or has excitement surrounding the company gotten ahead of itself?
Image source: The Motley Fool.
AI is becoming a meaningful contributor for SpaceX SpaceX's expansion into AI infrastructure might be the most underappreciated part of the story. Around the time of its IPO, the company signed compute agreements with Anthropic and Google. Since its public debut, SpaceX has expanded its AI customer list.
Reflection AI is spending roughly $150 million per month to rent a cluster of Nvidia GB300 chips at SpaceX's Colossus 2 data center. The deal value could be worth up to $6.3 billion over the entire life of the contract. During SpaceX's Q2 earnings call, management disclosed the company signed a six-month cloud services agreement worth $6.7 billion and noted that capacity will ramp throughout October. Most recently, SpaceX CFO Bret Johnsen shared with investors another hosting agreement worth approximately $1.11 billion per month, or $13.3 billion annually.
Taken together, SpaceX is forecasting its combined businesses could reach a $100 billion annualized revenue run rate by December. This is important because this growth underscores how the company is diversifying beyond its roots in launch services. SpaceX is proving it can build AI infrastructure at hyperscale speed, sell compute capacity to some of the world's fastest-growing technology companies, operate a high-margin connectivity provider in Starlink, and potentially use its own rockets to launch computing infrastructure into orbit.
Today's Change
(
0.48
%) $
0.83
Current Price
$
171.92
A trifecta of launch milestones The last several days were a good showcase of SpaceX's other competitive advantage: launch cadence. On Sept. 28, Starship reached orbit for the first time and successfully deployed 26 Starlink V3 satellites. Although the mission ended earlier than originally planned following an engine issue, successfully putting an operational payload into orbit represents an unprecedented step toward making Starship commercially useful.
A trifecta of launch sequences subsequently occurred on Oct. 1. SpaceX launched Crew-13 to the International Space Station (ISS) for NASA, further validating Falcon 9 and Dragon as capable human-spaceflight infrastructure.
A few hours later, the company carried 130 payloads into orbit as part of the Transporter-18 mission. Of note, one was Google's prototype satellite for Project Suncatcher, an experiment testing whether its custom silicon, called Tensor Processing Units (TPUs), could support AI computing in space. This mission is particularly interesting given Google's existing relationship with SpaceX on terrestrial AI compute.
Finally, SpaceX's Falcon Heavy was part of a classified launch, called NROL-97. Participating in a mission for the National Reconnaissance Office mission expands SpaceX's role beyond commercial deployments into national security launches.
Should you buy SpaceX stock before earnings? I'll admit that SpaceX's business looks stronger now than it did a few months ago. But that doesn't automatically make SpaceX stock a screaming buy in October. The company is already valued at roughly $2 trillion, meaning investors aren't exactly discovering a new growth story. Moreover, SpaceX still carries hefty losses as it invests aggressively in AI infrastructure and Starship.
With earnings just a few weeks away, SpaceX really needs to demonstrate that its compute contracts are translating into revenue and improving economics -- not merely generating buzzy headlines. With this in mind, I wouldn't view October as a month to chase SpaceX's momentum simply because Starship reached orbit or several launches went well.
For long-term investors, the bigger thesis remains compelling. SpaceX increasingly sits at the intersection of AI, satellite internet, government infrastructure, and commercial spaceflight. Investors who want exposure to the company are best off using dollar-cost averaging --building a position gradually at different price points over time rather than making earnings day an all-or-nothing bet.
Nautilus Advisors ve třetím čtvrtletí zvýšil svou pozici ve společnosti SpaceX o 153,4 % nákupem 5 628 akcií, čímž celkový počet akcií zvýšil na 9 297.
Nautilus Advisors LLC increased its stake in SpaceX (NASDAQ:SPCX – Free Report) by 153.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,297 shares of the company’s stock after purchasing an additional 5,628 shares during the quarter. SpaceX accounts for 0.9% of Nautilus Advisors LLC’s investment portfolio, making the stock its 27th largest position. Nautilus Advisors LLC’s holdings in SpaceX were worth $1,403,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Syntax Research Inc. acquired a new position in SpaceX during the second quarter worth about $26,000. Atwood & Palmer Inc. acquired a new stake in shares of SpaceX during the 2nd quarter valued at approximately $29,000. PayPay Securities Corp purchased a new stake in shares of SpaceX during the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC acquired a new stake in shares of SpaceX in the 2nd quarter worth approximately $32,000. Finally, Hickory Point Bank & Trust acquired a new stake in shares of SpaceX in the 3rd quarter worth approximately $30,000.
Analyst Ratings Changes Several equities analysts recently issued reports on SPCX shares. Piper Sandler reduced their price objective on SpaceX from $156.00 to $140.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. TD Cowen initiated coverage on SpaceX in a report on Monday, September 28th. They issued a “buy” rating and a $200.00 target price on the stock. Roth Capital upgraded SpaceX to a “buy” rating in a research report on Monday, June 22nd. Raymond James Financial downgraded SpaceX from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, August 7th. Finally, KeyCorp reiterated a “sector weight” rating on shares of SpaceX in a research report on Tuesday, July 28th. Three research analysts have rated the stock with a Strong Buy rating, twenty-seven have assigned a Buy rating, seven have issued a Hold rating and seven have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $218.68.
Get Our Latest Stock Report on SPCX Insider Activity at SpaceX In related news, COO Gwynne Shotwell sold 342,170 shares of SpaceX stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $153.57, for a total transaction of $52,547,046.90. Following the completion of the sale, the chief operating officer owned 2,472,035 shares in the company, valued at approximately $379,630,414.95. This trade represents a 12.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
SpaceX Price Performance Shares of SpaceX stock opened at $171.92 on Wednesday. SpaceX has a 1 year low of $104.83 and a 1 year high of $225.64. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.12 and a quick ratio of 4.99. The stock’s 50 day moving average is $141.88. The firm has a market cap of $2.27 trillion and a P/E ratio of -1,910.22.
SpaceX (NASDAQ:SPCX – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.17. The company had revenue of $7.81 billion for the quarter. The business’s revenue was up 91.9% on a year-over-year basis. As a group, research analysts expect that SpaceX will post 0.09 EPS for the current fiscal year.
Key Stories Impacting SpaceX Here are the key news stories impacting SpaceX this week:
Positive Sentiment: Morgan Stanley reiterated a $300 price target and Buy-equivalent rating, calling SpaceX “cheap and getting cheaper” on a growth-adjusted basis. The firm sees significant potential in AI computing, Starlink, and the company’s ability to address power and chip constraints. SpaceX Stock Jumps on Bullish Morgan Stanley Call Positive Sentiment: Operational milestones strengthened the growth narrative. Crew-13 reportedly reached the International Space Station in a NASA-record time, while recent Starship progress and multiple successful launches support SpaceX’s expanding launch cadence and commercial ambitions. SpaceX Crew-13 Shatters NASA Speed Record Positive Sentiment: Starlink reportedly surpassed 12 million subscribers, providing evidence of continued satellite-internet expansion. Investors are also assigning value to potential AI-compute customers, including reported discussions with Microsoft, and possible chip-manufacturing cooperation involving TSMC. Morgan Stanley and TD Cowen Back SpaceX Neutral Sentiment: Options markets indicate a slower recovery may be ahead. Although SPCX has reclaimed its debut close, relatively subdued volatility and cautious option pricing suggest traders do not expect an immediate return to the post-IPO high near $225. SpaceX Stock Is Taking Off Again Negative Sentiment: A reported plan to raise approximately $40 billion could pressure the stock. The financing may fund ambitious AI infrastructure and space projects, but it also raises concerns about substantial capital needs, leverage, or shareholder dilution. Why SpaceX Stock Is Down After Hours Negative Sentiment: Valuation and near-term supply risks remain significant. Critics argue the stock already reflects considerable Starlink and AI success, while up to 328.4 million shares may become eligible for sale on October 9. The potential increase in tradable shares could create selling pressure after the recent rally. SpaceX Stock Gains Ahead of Share Unlock SpaceX Profile (Free Report)
Space Exploration Technologies Corp. (SpaceX) is a privately held aerospace company founded in 2002 by Elon Musk. The company develops and operates launch vehicles, spacecraft and satellite systems designed to reduce the cost of access to space and support commercial, government and scientific missions.
SpaceX’s primary products and services include the Falcon 9 and Falcon Heavy launch vehicles, the Dragon spacecraft and the Starlink satellite internet network. The company also is developing Starship, a fully reusable launch and spacecraft system intended for missions to Earth orbit, the Moon and Mars.
Recommended Stories Five stocks we like better than SpaceX Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for SpaceX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpaceX and related companies with MarketBeat.com's FREE daily email newsletter.
Aplikace Muse od Meta je i nadále nejstahovanější bezplatnou aplikací pro iOS; akcie společnosti Meta od jejího spuštění před měsícem vzrostly přibližně o 20 %. Klíčové bude udržet si uživatele.
Meta's Muse personal agent has been topping app store charts. Now, the "centerpiece" of the company's artificial intelligence strategy, as CEO Mark Zuckerberg describes it, needs to become something people make a habit of using.
The buzz around Meta's AI agent has excited investors. The stock is up about 20% since the app's launch a month ago and recorded its best month in September since 2022.
While Meta is still currently the top free app on Apple's iOS store, the bigger challenge for the Facebook parent is to get people to keep using Muse after the magic wears off. Meta needs its personal agent to be an anchor app for the company, which has been trailing competitors like OpenAI and Google in the red-hot AI market.
"Muse has an opportunity to be sticky with consumers because it's a task-completer, rather than just a chatbot," Meredith Whalen, chief research officer at IDC, said in an email.
Whalen said consumers are using current AI tools for a range of tasks, but it's unclear if they'll be willing to hand over the kind of personal data required to create an efficient digital assistant. That's a particularly big obstacle for Meta, which just agreed to an almost $17 billion settlement with a group of states that alleged the company misrepresented the extent of child mental health harms caused by apps like Facebook and Instagram.
"The real question is trust," Whalen said.
Meta is pitching Muse to both consumers and small businesses for tasks like organizing personal emails, searching for shopping deals or seeking out prospective customers. Although Meta lets users access Muse for free, it also sells monthly subscription plans for $20 or $100, depending on tokens, a metric the company uses to calculate the power AI agents need to accomplish tasks.
In offering Muse for free out of the gate, the company can get an understanding of how and why people are using it, said Whalen, who noted that, "Price comes later, once the habit is established."
watch now
Coders have found AI agents helpful as software engineering tools, but the general public and even business leaders are still grappling with the potential for supercharged digital assistants, beyond acting as mere question-and-answering services.
"I would say that widely, enterprise-scale AI agent adoption is still page one, chapter one," said Ketan Karkhanis, CEO of ThoughtSpot, which sells AI agent technologies to businesses.
Consumers are just getting started with AI agents.
Karkhanis said he hasn't seen the kinds of "killer use cases" that would make apps like Muse more compelling than merely being a "next-gen Alexa" or Siri voice assistant that people might use to tell them the weather.
Andrew Geller, executive producer of 1stAveMachine, said his media firm develops its own internal agentic tools for certain production tasks. He views Muse and other consumer-focused AI agents as being "quite helpful" in introducing the technology to the masses, but says they're hardly life-changing.
Geller said he was "early on the OpenClaw train," referring to the so-called open-source harness for managing AI agents that took off earlier this year. He said he discovered that personal use of AI agents can be fun, but also "kind of a little banal," particularly when contrasted with the more heavy-duty uses related to coding.
Bring on the Personal AI assistantsA number of other tech firms are trying to commercialize AI agents for the masses by first enticing users to join for free.
Former Yahoo CEO Marissa Mayer is taking a try-before-you-buy approach with her new photo-centric AI agent startup Dazzle, a tactic she said is important "for those occasional users or those users who are just trying to see what the service can do at the very beginning."
Dazzle analyzes users' personal photos to understand aspects of their lives, such as their family members or interests, and then can take actions like reminding someone that a pair of shoes they recently looked up is on sale online.
It's a strategy she learned from her early tenure at Google, before the company built its market-leading online ad platform.
"What we're really trying to do is see what use cases are really popping with users, what do they see as really helpful, and that will guide it," Mayer said about Dazzle's first week post-launch.
Mayer compared the pricing and adoption approach to Uber's evolution. The ride-hailing company began with black town cars before introducing lower-priced options for a wider swath of users.
"It's a luxury to be able to have these wonderful recommendations and to have this level of convenience," Mayer said.
Dazzle is considering transaction fees and subscriptions.
"We want to be running a service where people feel that they're getting value on a relatively continuous basis over time," Mayer said.
At Wajo AI, CEO Shivani Poddar is also contemplating business models for her new AI-powered digital assistant startup, which lets people research and book appointments or order gifts for family members.
Poddar, who has previously built voice-assistant technologies for Amazon Alexa and at Facebook, is letting people access the service for free for now. While Poddar believes businesses may be willing to pay subscription fees, she's not yet convinced that "the everyday person" will want to sign up, and instead may be more willing to pay service fees based on outcomes, like how Airbnb makes money from bookings.
The stakes are highest for Meta, which went on a massive spending spree last year to acquire talent and build a business in AI that could compete with OpenAI and Anthropic. Zuckerberg is desperate to diversify away from online ads, which still account for almost all of the company's revenue, and he's got a long way to go to prove that Muse can be a key piece of that effort.
Zuckerberg, at least to an extent, has time on his side.
"Whoever can subsidize users and wait has the advantage," IDC's Whalen said. "And Meta's ad business can pay for a lot of waiting."
Amazon v květnu spustil beta verzi stránky „About You“, která na základě aktivity zákazníků vytváří podrobné profily pro personalizaci uživatelského prostředí.
Why is Amazon keeping track of the size of shoppers’ butts?
That’s the question that brought one Amazon customer to social media, where she shared the discovery that left her “literally speechless.”
According to Threads user Megan Montgomery, she “stumbled upon a page of assumptions that Amazon has made,” which included statements based on her shopping habits. That included the details of events she’d hosted (“Prepared for a Bluey-themed 2nd birthday celebration”), products she’d purchased (“Probably owns a Shark vaccuum”), and—most shockingly—the shape of her body (“Has flat buttocks”).
Montgomery had accidentally opened Amazon’s “About you” page, which is currently in beta after launching this May. The page uses data from customers’ activity to generate details about them in categories like Product Preferences, Interests & Hobbies, and Home & Family, which allows Amazon to personalize the user experience.
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
In Montgomery’s comments, other users shared the strangest assumptions Amazon had made about them. One user shared that it said their “husband has skinny legs.” Another user’s account listed “cusses when scared” under their interests and hobbies. A third user’s account assumed that they like “brunettes with muscles,” much to their confusion.
Though many social media users are just discovering the feature, others have been discussing it since launch. On Reddit, one user complained that their “About you” page had seemingly pulled data from reviews they’d left. “I was absolutely stunned to see it saves these details I had put in my reviews and more,” they wrote. “Honestly, it seriously creeps me out.”
Amazon’s privacy policyThough some shoppers seemed shocked to learn Amazon was pulling information from their reviews, that’s only the tip of the iceberg of Amazon’s personal data collection.
AMD očekává ve 3. čtvrtletí tržby kolem 13 mld. USD; příspěvek platformy Helios se začne projevovat na konci čtvrtletí a výrazněji poroste ve 4. čtvrtletí.
AMD has surged past every analyst price target on the back of gigawatt-scale AI chip commitments, but the product that justifies this valuation has not yet shipped a single unit at scale.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AMD (NASDAQ:AMD | AMD Price Prediction) trades at $649.42. The stock is up 203.24% year to date and now trades above the average Wall Street price target. That leaves investors considering record growth against a very demanding multiple.
AMD designs CPUs and GPUs. It competes with NVIDIA (NASDAQ:NVDA) in AI accelerators and with Intel (NASDAQ:INTC) in server processors. Last quarter, revenue rose 50.11% to $11.54 billion, beating the $11.31 billion estimate. Data Center revenue climbed 107% and now makes up 58% of sales.
Gigawatt Deals Could Make Today’s Multiple Look Cheap Bulls look past trailing earnings. AMD trades at a forward P/E of about 40, and its PEG ratio of 0.626 is below 1, which suggests growth is exceeding price. The 2027 EPS consensus has increased to $15.5833 from $13.1770 90 days ago.
The customer list is strong. OpenAI has committed to 6 gigawatts of AMD GPUs, Meta Platforms (NASDAQ:META) to up to 6 GW, and Anthropic to up to 2 GW of MI450 chips in Helios racks. Management says Helios demand is “tracking ahead of our initial forecasts” and expects Data Center revenue to “more than double year-over-year in 2027.”
A Triple-Digit Trailing Multiple Leaves No Room for a Helios Stumble Bears point to a trailing P/E of about 161, a price-to-free-cash-flow ratio of 158 and a free cash flow yield of just 0.63%. Free cash flow fell 9.89% last quarter as capital spending jumped 186.52%.
Gaming revenue dropped 31%, and export controls cost about $440 million in fiscal 2025. Helios is complex, and management expects yields to improve only over the first few quarters of the ramp. With a beta of 2.454, any delay would hit a stock already priced for perfect execution.
Helios Shipments Will Decide Which Side Wins AMD guided third-quarter revenue to about $13 billion, with a non-GAAP gross margin near 56%. Helios starts contributing at the end of the third quarter, with a more substantial ramp in the fourth quarter. Anthropic’s first gigawatt begins in the first half of 2027.
Strong Helios revenue and increased 2027 estimates would support the optimistic thesis. Yield problems or customer delays tied to power and land preparation would support the pessimistic thesis. (We reverse-engineered what the biggest tech winners looked like early in a free report you can grab here.)
Shares Have Run Past the Average Analyst Target At $649.42, AMD sits above the consensus target of $629.21, which implies 3.1% downside. Price targets are only one data point, and these have trailed the rally. Of 55 analysts:
Strong Buy: 5 Buy: 39 Hold: 11 Sell: 0 AMD is up 218.8% over the past year, compared with 16.01% for the S&P 500. Over the past month it rose 35.98%, and the index added 1.16%. The stock trades near its 52-week high of $658.52 and well above its 50-day average of $513.53.
Helios Must Prove Itself Before AMD’s Multiple Makes Sense At $649.42, AMD trades on expectations that Helios still has to confirm.
Operations are running smoothly. The share price, however, already reflects about 42 times 2027 consensus EPS, so much of the expected growth is priced in. The optimistic thesis needs fourth-quarter Helios revenue to arrive on schedule and 2027 estimates to keep increased. The pessimistic scenario would need yield setbacks, slipping deployments, or free cash flow that keeps falling as capital spending grows.
Timing matters here. The stock sits above its consensus target after a one-month surge. A decline is possible if the next earnings report only matches guidance. The gigawatt-scale order pipeline, however, is still growing.
Over the next two quarters, keep an eye on Data Center growth, gross margin holding near 56%, Helios customer diversity, and capital spending versus free cash flow. AMD’s growth is real, and at this price the valuation depends on Helios showing up in the numbers.
Contact [email protected] for any questions or corrections.
BrewDog uvádí, že prodeje Punk IPA a Hazy Jane u šesti hlavních maloobchodních partnerů meziročně vzrostly na 2,87násobek ve srovnatelném dvoutýdenním období.
Bold UK-wide campaign puts craft beer back at the centre of culture, celebrating better ingredients, better quality, skilled brewers, beer lovers and the big flavours that make craft worth choosing.
BrewDog consumers are back: sales across the brand’s top six off-trade retailers are up 2.87 times for Punk IPA vs last year’s volume for the same two-week period as the Under New Ownership and Choose Craft campaigns roll out across the UK.
ELLON, Scotland, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is building commercial momentum under Tilray ownership, with a strong weekly sales snapshot and eight new on-trade partnerships spanning live entertainment, sport, pubs and hotels. Its UK-wide Choose Craft campaign will support that momentum, celebrating the quality, flavour and character that make craft beer worth choosing.
Choose Craft marks a confident new chapter for BrewDog and a rallying call for beer lovers across the UK. The campaign, by McCann Manchester, builds on the belief that quality still counts, the campaign celebrates the flavour, craft, creativity and attitude that set great beer apart, and signals BrewDog’s renewed momentum as it champions the category it helped define. The momentum is already showing at retail: since BrewDog began rolling out Choose Craft, EPOS data shows sales across its top six off-trade retailers are up 2.87 times for Punk IPA and Hazy Jane vs last year’s volume for the same two-week period as the Under New Ownership and Choose Craft campaigns roll out across the UK. Building on that momentum, new BrewDog craft beer innovation has secured more than 9,000 new distribution points across the UK. Alongside that retail momentum, BrewDog has secured eight new on-trade partnerships since Tilray took ownership, expanding its presence across live entertainment, sport, pubs and hotels. These include an Official Beer Partner agreement with Underbelly, bringing BrewDog’s full range to Edinburgh Fringe, Boulevard Soho, Skate in Leicester Square and Skate in Trafalgar Square, and a five-year Official Beer Partner agreement with Leicester Tigers. As well as some high profile on trade accounts such as Ladhar, Kew Green and Malones.
Choose Craft is rolling out now across the UK through bold, high-visibility placements, including murals in Manchester and Edinburgh, static and digital advertising across major national railway and underground stations, roadside locations and proximity advertising near key stockists. More than visibility, the campaign is designed to remind beer lovers why craft became a movement: quality ingredients, distinctive flavour, bold ideas and the details that make beer something people actively seek out, talk about and choose with pride.
For BrewDog, the message is clear: the brand is back with purpose, energy and a sharper point of view. Following its Under New Ownership campaign, BrewDog is building on the spirit that made it iconic — uncompromising beer, a passionate community and a belief that craft should lead culture, not follow it.
John Beasley, Chief Marketing Officer, comments: “Choose Craft is a campaign with conviction. It is about putting quality, flavour and the craft beer community back in the spotlight — and reminding beer lovers across the UK why great beer is worth choosing. BrewDog is back with confidence, focus and momentum. We have always believed beer should have character, flavour and attitude. As the UK’s leading craft beer brand, we have a responsibility to champion quality, celebrate the brewers and beer lovers who built this movement, and give people every reason to choose craft.”
BrewDog is giving beer lovers more ways to join in and choose craft, including a grocery and BrewDog.com promotion on 10-packs of Lost Lager for £10, a Tesco-exclusive competition inviting shoppers to help create the next BrewDog beer, and a Scratch to Win mechanic across the on-trade, with experiential activations and customer moments designed to celebrate craft beer where people discover, buy and enjoy it.
Innovation That Raises the Bar for Craft
The campaign is also backed by a fresh wave of craft innovation from BrewDog. With discovery the #2 choice driver in craft after taste, BrewDog is keeping new flavours, formats and beer experiences front and centre. Premium 440ml cans account for 27% of craft sales and attract the category’s most engaged and highest-value shoppers, who spend three times as much as the average craft consumer. BrewDog’s latest beers, alongside the recent Liquid Visions launch, build on that appetite for discovery while reinforcing the brand’s commitment to quality, creativity and choice.
First up, West Coast Session IPA, Palm Break (330ml, 4% ABV), brings bright, easy-drinking craft refreshment with a West Coast edge. Light in body yet full in character, it balances lush fruit notes with a clean snap of bitterness, leaving a refreshing, resin-kissed afterglow.
With the stout market growing at +9.1%, Hazelnut Heist (440ml, 8% ABV) leans into continued consumer interest in rich, indulgent stout styles, particularly over the winter period. A decadent chocolate vanilla stout, it is loaded with roasted hazelnut, smooth vanilla and rich cocoa.
Raspberry Ripple New England IPA, Tripple Ripple (440ml, 6% ABV), is the latest collaboration with Mackie’s Ice Cream, bringing a playful, flavour-led twist to the craft category. It follows the phenomenal performance of the first Mackie’s collab, Two Scoops Stout, which was the #1 NPD brand in the craft category in the six months post-launch and recently won Gold at the World Beer Awards.
Finally, Cloud Engine (440ml, 8% ABV) is a Double Dry Hopped New England IPA that delivers a flavour bomb of mango, passionfruit and ripe citrus, with a silky mouthfeel and none of the bitterness.
About BrewDog
BrewDog has always had one mission: making people as passionate about great beer as we are.
From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007.
Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognizable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future will continue to be shaped by the three things that matter most: People, Planet and Beer.
For more information, visit www.brewdog.com or follow @BrewDog on social media.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/537bf3f1-1e5d-4c0f-a2a7-372bd44bc76a
https://www.globenewswire.com/NewsRoom/AttachmentNg/e09104a1-231d-4281-a04b-ecc47e83d668
https://www.globenewswire.com/NewsRoom/AttachmentNg/a7acfb3e-7c16-4e3e-a72f-6b5dc40e0951
https://www.globenewswire.com/NewsRoom/AttachmentNg/05b2ee85-43f9-4f7a-a6b0-b9c131fcfec1
https://www.globenewswire.com/NewsRoom/AttachmentNg/50ae3053-9cd8-4ae5-aecb-55d019832f64
https://www.globenewswire.com/NewsRoom/AttachmentNg/48783ec8-0ee2-4c88-8a55-559a2c6dcf44
Anthropic uvádí, že rozvoj AI omezuje především dostupnost výpočetního výkonu, a během příští dekády plánuje utratit 518 miliard USD, což podporuje poptávku po hardwaru společnosti Nvidia.
One of the most anticipated initial public offerings (IPOs) of 2026 could be coming shortly: Anthropic. Anthropic is an artificial intelligence (AI) lab that makes the Claude family of large language models. Anthropic has emerged as one of the leading companies in this area, and the market has been clamoring for it to go public for a while. Some estimates value the IPO at as much as $2 trillion, which is a very expensive price tag for how much the company generates and how much money it's losing. However, there will still be a large chunk of investors who buy in at the IPO. This may cause a short-term rally, but after that, the stock may need to show some profitability improvements to be considered a great long-term pick.
However, one statement in the leaked Anthropic prospectus drives me to conclude that investors should be buying up stocks of computing unit suppliers. The leader in this segment is Nvidia (NVDA +0.14%), and it looks like it could be a great stock to buy now based on these comments from Anthropic.
Image source: Getty Images.
AI could be much more advanced than it is now One of the most incredible statements from Anthropic in its prospectus document, according to Reuters, is that AI is "limited principally by the availability of compute." That's an incredible statement, as it basically says that if we had more computing power, we could be more advanced.
One of the primary reasons for Anthropic to go public is so it can have access to more funding sources, as it can raise money through debt issuance as well as by issuing more shares in the market. Anthropic isn't being shy about how much it's planning to spend, either: $518 billion during the next decade. That's a huge amount of growth ahead, and it could even be underestimating that if more compute becomes available.
Anthropic tells prospective investors that it doesn't believe demand will be an issue, just computing supply. That bodes well for companies like Nvidia, as it's supplying a large chunk of the computing power to the AI industry.
Nvidia's investment thesis hinges on supply constraints Computing unit suppliers like Nvidia still cannot make enough hardware to satisfy the demand from AI hyperscalers. In fact, Nvidia's forecast for growth of 70% during the next fiscal year hinges on the industry remaining supply-constrained. However, Anthropic believes this condition will persist for some time, continuing to drive AI hyperscalers to pay sky-high prices for computing units.
Premium Feature
Moneyball Superscore
95/100
Today's Change
(
0.14
%) $
0.34
Current Price
$
239.24
This benefits Nvidia and its peers, and as I think about the consequences of a company like Anthropic going public, it pushes me to invest in Nvidia and other computing unit suppliers rather than Anthropic. Anthropic has a lot to prove with its business model, as it must build a huge subscription base that uses its products. It's likely, but it requires an enormous audience for the finances to make sense.
Let's say 1 billion people pay a $50 monthly subscription for Anthropic's product. That will generate $600 billion in revenue per year. That's an extremely bullish projection and a huge amount of money, but consider this: Wall Street analysts expect Nvidia to generate nearly $700 billion in 2028.
What does this mean? I think it's pretty simple. Nvidia is the world's most value company. It took it more than three decades to reach that point and it has prospered in recent years amid enormous AI spending. Anthropic has a long way to go before it's a viable business, much less a company on par with Nvidia -- and there's a lot of risk ahead.
This makes Nvidia an excellent long-term investment, as companies like Anthropic will fuel its growth. As a result, I'm more interested in buying Nvidia than I am in Anthropic.
Mastercard Incorporated (NYSE:MA – Get Free Report) declared a quarterly dividend on Tuesday, September 29th. Shareholders of record on Friday, October 9th will be paid a dividend of $0.87 per share by the credit services provider on Monday, November 9th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, October 9th.
Mastercard has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 13 years. Mastercard has a payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Mastercard to earn $22.93 per share next year, which means the company should continue to be able to cover its $3.48 annual dividend with an expected future payout ratio of 15.2%.
Mastercard Stock Performance NYSE MA opened at $566.69 on Wednesday. Mastercard has a twelve month low of $464.52 and a twelve month high of $601.23. The business’s 50-day moving average price is $571.91 and its 200 day moving average price is $529.64. The company has a market capitalization of $496.43 billion, a PE ratio of 31.17, a price-to-earnings-growth ratio of 1.61 and a beta of 0.76. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 3.96.
Mastercard (NYSE:MA – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The credit services provider reported $5.04 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.27. The company had revenue of $9.28 billion for the quarter, compared to the consensus estimate of $9.08 billion. Mastercard had a net margin of 46.34% and a return on equity of 239.99%. Mastercard’s revenue was up 14.1% on a year-over-year basis. During the same quarter last year, the firm posted $4.15 earnings per share. On average, research analysts predict that Mastercard will post 19.9 earnings per share for the current year. Analysts Set New Price Targets MA has been the topic of a number of recent research reports. Keefe, Bruyette & Woods boosted their price objective on Mastercard from $665.00 to $685.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Daiwa Securities Group upped their target price on shares of Mastercard from $580.00 to $650.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Bank of America raised their price target on shares of Mastercard from $700.00 to $735.00 and gave the company a “buy” rating in a report on Friday, July 31st. BMO Capital Markets lifted their price target on shares of Mastercard from $580.00 to $630.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Evercore upped their price objective on shares of Mastercard from $550.00 to $620.00 in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, thirty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $680.00.
Read Our Latest Stock Analysis on MA
Mastercard Company Profile (Get Free Report)
Mastercard Incorporated (NYSE: MA) is a global payments technology company that operates a network connecting consumers, financial institutions, merchants, governments and businesses. The company facilitates the authorization, clearing and settlement of electronic payment transactions, while generally not issuing cards or extending credit itself. Its network supports payments made in stores, online and through mobile devices.
Mastercard’s products and services include consumer and commercial payment cards, digital payment solutions, payment processing, fraud prevention, cybersecurity, identity verification, data and analytics, and open banking tools.
Recommended Stories Five stocks we like better than Mastercard Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September
Receive News & Ratings for Mastercard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mastercard and related companies with MarketBeat.com's FREE daily email newsletter.
Divize zážitků společnosti Walt Disney ve 3. čtvrtletí 2026 zvýšila tržby o 10 % na 10 mld. USD a provozní zisk o 20 %; podílela se 54 % na celkovém provozním zisku.
Walt Disney (DIS +0.41%) has historically been known as a leader in cable TV, thanks to popular networks like ABC and ESPN. In recent years, the company's streaming operations have gotten a lot of attention, thanks to the success of Disney+ and Hulu, as well as the launch of the stand-alone ESPN platform.
These are important to Walt Disney, to be sure. However, investors should understand that these parts of the business pale in comparison to the entertainment stock's most lucrative segment.
Image source: The Motley Fool.
During third-quarter 2026 (ended June 27), Disney's experiences segment posted 10% year-over-year revenue growth. This was a better gain than any other segment. Its sales figure of $10 billion accounted for 40% of the entire company's total.
Operating income for experiences soared 20%. This profit metric represented 54% of the company's total operating income.
Premium Feature
Moneyball Superscore
75/100
Today's Change
(
0.41
%) $
0.42
Current Price
$
104.03
The experiences segment includes the theme parks and cruises. These make up what is arguably the most competitively advantaged segment of the business. They have high barriers to entry, and because Disney owns an immense portfolio of intellectual property, these experiences are differentiated in the industry. Consequently, they have historically had pricing power.
Despite the scale of this division, there is still a sizable growth runway to capture. In September 2023, the management team announced a 10-year, $60 billion capital investment plan to bolster the experiences segment in an effort to reach more people around the world. This can support the overall company's long-term financial performance.
Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Walt Disney. The Motley Fool has a disclosure policy.
BlackRock během čtyř burzovních dnů do 6. října zvýšil své kryptoměnové portfolio o 291,7 milionu USD: IBIT nakoupil BTC v hodnotě 545,57 milionu USD, zatímco ETHA prodal ETH v hodnotě 253,87 milionu USD.
Even though the cryptocurrency market saw choppy consolidation during the first week of October 2026, BlackRock Inc.’s (NYSE: BLK) crypto portfolio added more than $291 million.
BlackRock’s crypto portfolio surged by $291.7 million during the past four exchange-trading days through October 6, according to data Finbold analyzed from SoSoValue on October 7.
BlackRock’s iShares Bitcoin Trust (IBIT) purchased Bitcoin (BTC) worth $545.57 million between October 1 and 6. As such, IBIT increased its net assets to $9.62 billion.
BlackRock’s IBIT daily cash flow. Source: SoSoValue BlackRock’s iShares Ethereum Trust ETF (ETHA) divested Ethereum (ETH) valued at $253.87 million over the past four exchange-trading days. On October 6, ETHA’s net assets dropped by approximately $201.89 million, its largest single-day decline since January 21.
BlackRock’s IBIT daily cash flow. Source: SoSoValue As such, BlackRock’s ETHA held 3,656,389.78 Ethereum, currently worth over $9.8 billion, as per its official website.
Bitcoin and Ethereum price action amid BlackRock’s transfers As this fund manager accumulated over 4,000 Bitcoin during the past four days, BTC price climbed roughly 1.13%, trading at about $83,960 at the time of writing. Consequently, Bitcoin had a market capitalization of about $1.7 trillion.
BTC price performance for the past 7 days. Source: Finbold On the other hand, Ethereum’s price had fallen by over 3% at the time of reporting, retesting $2,597. This altcoin has a market cap of $314.7 billion.
Ethereum price performance for the past 7 days. Source: Finbold During the past 24 hours, Ethereum’s trading volume surged by over 70% to $18.2 billion as per metrics from CoinMarketCap.
As a result, BlackRock’s Bitcoin and Ethereum transfers over the past four exchange-trading days influenced their price performance over the last seven days.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Před zveřejněním výsledků za 3. čtvrtletí vyplácí PepsiCo čtvrtletní dividendu ve výši 1,48 USD na akcii, což odpovídá ročnímu dividendovému výnosu 4,71 %.
PepsiCo, Inc. (NASDAQ:PEP) will release third-quarter earnings before the opening bell on Thursday, Oct. 8.
With the recent buzz around PepsiCo, some investors may be eyeing potential gains from the soft drink company’s dividends too. As of now, PepsiCo has an annual dividend yield of 4.71%, based on a quarterly dividend of $1.48 per share ($5.92 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month, or $6,000 annually, from dividends alone, you would need an investment of about $127,470, or around 1,014 shares. For a more modest $100 per month or $1,200 per year, you would need $25,519 or around 203 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($5.92 in this case). So, $6,000 / $5.92 = 1,014 ($500 per month), and $1,200 / $5.92 = 203 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as dividend payments and stock prices both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock’s current price.
For example, if a stock pays an annual dividend of $2 and trades at $50, the dividend yield is 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in dividend payments can affect yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, the yield will also decrease.
Price ActionPepsiCo shares rose 0.1% to close at $125.71 on Tuesday.
Analysts expect the company to report quarterly earnings of $2.30 per share, up from $2.29 per share a year ago. The consensus estimate for PEP’s quarterly revenue is $24.96 billion. It reported $23.94 billion last year, according to Benzinga Pro.
Ahead of quarterly earnings, RBC Capital analyst Nik Modi, on Tuesday, maintained PepsiCo with a Sector Perform and lowered the price target from $161 to $150.
Qualcomm očekává, že dva kontrakty na zakázkové čipy pro hyperscalové poskytovatele začnou přinášet tržby ve čtvrtletí končícím v prosinci. Do fiskálního roku 2029 cílí na tržby z datových center ve výši více než 15 mld. USD.
Qualcomm still gets priced like a smartphone supplier, but two hyperscaler custom silicon deals about to generate revenue suggest the market is missing something significant about where this company is actually headed.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The 24/7 Wall St. price target for Qualcomm (NASDAQ:QCOM | QCOM Price Prediction) is $225.99 over the next 12 months. The target sits 22.24% above the $184.87 close. The stock carries a buy rating with high confidence.
24/7 Wall St. Price Target Summary Metric Value Current Price $184.87 Price Target from 24/7 Wall St. $225.99 Upside/Downside 22.24% Recommendation BUY Confidence Level 90% My thesis: Qualcomm trades at a handset-supplier multiple of 20x forward earnings, yet management guides to $40 billion in non-handset revenue by fiscal 2029, with more than $15 billion from data center. Two hyperscaler custom silicon wins begin generating revenue in the December quarter.
Investor Day Rally Faded, but Momentum Is Rebuilding Shares fell 8.19% over the past week but are up 9.7% over the past month and 12.13% over the past year. The 52-week range runs from $120.88 to $257.56. The stock rose from $129.39 in mid-March to $220.81 in mid-June, ahead of the June 24 Investor Day.
In fiscal Q3, revenue of $9.95B beat the $9.67B consensus. Non-GAAP EPS of $2.21 just missed the $2.2208 estimate. Handsets dropped 20%. Automotive rose 61% to $1.59B.
Why Bulls See $243 or More Management expects data center revenue of $5 billion in fiscal 2027, rising to $15 billion in fiscal 2029. Qualcomm has taped out its first high bandwidth compute chip, launching in mid-2027. The Modular acquisition adds an open, hardware-agnostic AI software stack.
CEO Cristiano Amon expects non-handset growth to speed up to “greater than 60% in fiscal 2027″. Automotive is expected to exit fiscal 2026 at an annualized pace of about $7 billion.
Only 11 analysts have a positive rating on the stock, against 23 Holds, leaving room for upgrades. The bull case is $243.19.
Handset Pressure and Margin Drag Could Cap Gains Operating income fell 41.13% year over year from spending on the Modular deal plus the data center plan. Management expects early custom-chip revenue to cut QCT gross margin by one and a half to 2%.
Risks include China exposure, rising input costs, and customers designing their own chips. Management says a handset recovery could add greater than $1.50 of EPS once markets normalize. The bear case is $190.83.
Qualcomm Trades at a Discount to Custom Silicon Rivals Company Forward P/E Trailing P/E Qualcomm 20x 21x Broadcom 19x 44x Marvell 62x 90x Broadcom (NASDAQ:AVGO) is the leading supplier of custom AI chips to hyperscalers, Qualcomm’s target customers. Its forward multiple is close to Qualcomm’s, yet Broadcom posted 85.5% quarterly revenue growth while Qualcomm’s revenue fell 4%. Qualcomm’s data center expansion must deliver to earn a similar rerating.
Marvell (NASDAQ:MRVL) makes custom data center silicon with a market cap of $244.7 billion versus Qualcomm’s $197.45 billion. Investors pay a far higher forward multiple for Marvell’s AI growth. Our target implies about 23x forward earnings, which looks conservative against this peer group.
Qualcomm Price Prediction 2026-2030 The 24/7 Wall St. price target of $225.99 comes with a buy rating and 90% confidence. The deciding factor is the data center expansion.
The bull case improves if custom silicon revenue arrives on schedule in the December quarter. At about 20x forward earnings, the AI upside does not look priced in.
Looking further out, this is where our model projects Qualcomm could trade, assuming current growth trends and market conditions hold.
Year Price Target from 24/7 Wall St. 2026 $197.56 2027 $225.99 2028 $252.57 2029 $298.76 2030 $316.58 Qualcomm would need to keep executing on its diversification strategy for these projections to hold. Results could move well above or below them depending on hyperscaler adoption of the high bandwidth compute chip and on how quickly handset demand rebounds.
Contact [email protected] for any questions or corrections.
Pfizer Inc. (NYSE:PFE – Get Free Report) declared a quarterly dividend on Tuesday, October 6th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th.
Pfizer has decreased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.
Pfizer Stock Performance Shares of PFE stock opened at $27.48 on Wednesday. The company has a market capitalization of $156.63 billion, a price-to-earnings ratio of 36.16, a P/E/G ratio of 1.84 and a beta of 0.32. Pfizer has a 1-year low of $23.62 and a 1-year high of $29.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock’s fifty day simple moving average is $27.50 and its 200-day simple moving average is $26.48.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business earned $0.78 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer will post 2.98 earnings per share for the current fiscal year. Hedge Funds Weigh In On Pfizer Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Moody National Bank Trust Division lifted its stake in Pfizer by 3.7% in the third quarter. Moody National Bank Trust Division now owns 86,627 shares of the biopharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 3,061 shares during the last quarter. Legacy Private Trust Co. acquired a new position in shares of Pfizer during the 3rd quarter worth $207,000. Park National Corp OH raised its holdings in shares of Pfizer by 6.4% during the 3rd quarter. Park National Corp OH now owns 257,556 shares of the biopharmaceutical company’s stock valued at $7,345,000 after purchasing an additional 15,475 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its stake in shares of Pfizer by 35.0% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 12,951 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 3,361 shares during the last quarter. Finally, Argent Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at $8,128,000. Institutional investors own 68.36% of the company’s stock.
About Pfizer (Get Free Report)
Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.
The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.
See Also Five stocks we like better than Pfizer Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
Before a single AI chip reaches a fab, it passes through Synopsys software, and that chokepoint keeps getting harder to route around. Here is why a stretched valuation, ten billion dollars of acquisition debt, and slowing EDA growth have not…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
I have added Synopsys (NASDAQ:SNPS | SNPS Price Prediction) after every earnings report this year. Before any AI chip reaches a fab, engineers design, verify, and sign off on it using Synopsys software. Each new chip generation is harder to build, requiring more tools, licenses, and simulation. I want to own that toll road for the next decade.
Growth That Keeps Beating the Forecasts Fiscal Q3 revenue reached $2.48B, up 42.4% YoY. Non-GAAP EPS of $3.91 beat the $3.67 consensus by 6.44%, which makes four straight beats. Management then raised full-year guidance for the second time. Non-GAAP EPS guidance has been raised to $15.04 to $15.10, up from an original $14.38 to $14.46, and free cash flow guidance is about $2.6B.
Ansys is pulling its weight. Management expects it to contribute about $2.98 billion this year, $20 million above prior guidance. The company targets $400 million in cost synergies by year four. Joint products like Multiphysics Fusion should add to EDA growth in fiscal 2027.
A Moat Built on Sign-Off Trust EDA runs as a duopoly. Backlog stood at $10.9 billion at Q3 end. CEO Sassine Ghazi noted: “Customers will not invest hundreds of millions of dollars in a product without having the confidence that it is going to work.” Synopsys won more than 95% of PCIe 7 opportunities, and its die-to-die business is on pace to double.
Why My Money Goes Here Instead of Cadence Cadence Design Systems (NASDAQ:CDNS) is the alternative. Cadence trades at a forward P/E of 32 and 16.68 times sales. Synopsys trades at a forward P/E of 23 and 9.94 times sales. The stock rose 21.7% last week to $505.17, and even at that price it sits near 27x the $18.583 fiscal 2027 consensus.
Debt and Integration Risks I Refuse to Ignore Ansys left Synopsys carrying about $10 billion of debt. Restructuring charges should total $200M to $250M this fiscal year, and roughly $403M of quarterly amortization drives the trailing P/E to 86. China export controls, a short customer list, and shareholder lawsuits over Design IP add risk. Q3 EDA growth slowed to 8.5%.
None of that has changed my thesis. Management repaid $3.46B of debt in the first half and paid off term loans early. Total liabilities fell 19.6% YoY, and cash rose to $3.61B. Double-digit organic EDA growth is also expected in Q4 and for the full year.
What Keeps My Buy Button Active Analysts made 18 upward revisions to fiscal 2027 EPS over the past seven days, with none lower. Royalty-based custom IP, agentic AI workflows, and joint Ansys products sit ahead. Synopsys pays no dividend. The stock has returned 752.46% over ten years. Chips keep getting harder to design, Synopsys sends a bill for every added layer of difficulty, and I expect to own a bigger share of those bills.
Contact [email protected] for any questions or corrections.
Společnost MetLife vyplatí 8. prosince čtvrtletní dividendu ve výši 0,5925 USD na akcii akcionářům evidovaným k 3. listopadu; v přepočtu na celý rok činí dividenda 2,37 USD.
MetLife, Inc. (NYSE:MET – Get Free Report) announced a quarterly dividend on Tuesday, October 6th. Shareholders of record on Tuesday, November 3rd will be paid a dividend of $0.5925 per share by the financial services provider on Tuesday, December 8th. This represents a $2.37 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, November 3rd.
MetLife has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 12 consecutive years. MetLife has a payout ratio of 22.9% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect MetLife to earn $10.70 per share next year, which means the company should continue to be able to cover its $2.37 annual dividend with an expected future payout ratio of 22.1%.
MetLife Stock Performance Shares of MET stock opened at $97.22 on Wednesday. The company has a market capitalization of $62.56 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 0.92 and a beta of 0.78. MetLife has a 52 week low of $67.33 and a 52 week high of $100.93. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20. The company’s 50 day moving average price is $96.53 and its two-hundred day moving average price is $87.17.
MetLife (NYSE:MET – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The business had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. During the same period last year, the business posted $2.02 earnings per share. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts expect that MetLife will post 9.85 earnings per share for the current fiscal year. Analysts Set New Price Targets A number of research firms recently issued reports on MET. Mizuho increased their price objective on MetLife from $95.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research note on Friday, September 11th. Wells Fargo & Company boosted their price objective on shares of MetLife from $101.00 to $109.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. TD Cowen increased their target price on shares of MetLife from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Finally, Morgan Stanley lifted their price target on shares of MetLife from $103.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday, August 24th. Twelve investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $105.08.
View Our Latest Report on MET
About MetLife (Get Free Report)
MetLife, Inc is a global financial services company that provides insurance, employee benefits and retirement solutions. Its products and services include life insurance, dental and vision coverage, disability insurance, accident and health benefits, annuities, and savings and retirement products.
The company serves individuals, employers and institutions through group benefits, workplace solutions and individual insurance offerings. MetLife also provides investment and retirement services designed to help employers and employees prepare for long-term financial needs.
Founded in 1868, MetLife is headquartered in New York City and operates through businesses in the United States and international markets, including regions across Latin America, Asia and Europe.
See Also Five stocks we like better than MetLife Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.
Společnost BD uvedla, že stent Revello dosáhl v devítiměsíční studii AGILITY primární průchodnosti 97,2 % a splnil hlavní bezpečnostní a účinnostní cíl.
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.
, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease (PAD). The findings mark an important milestone in the efforts by BD to expand clinical evidence supporting innovative solutions for chronic vascular disease and reinforce its commitment to advancing care for patients with PAD.
New AGILITY trial data presented at VIVA 2026 reinforce BD’s commitment to advancing peripheral vascular care. Nine-month results from the iliac cohort showed strong safety and effectiveness outcomes for the Revello™ Vascular Covered Stent, including 97.2% primary patency and 98.3% freedom from clinically driven target lesion revascularization. Together, these findings expand the growing body of evidence supporting innovative treatment options for patients with PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello™ Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries.
Iliac artery disease can reduce blood flow to the legs and feet and potentially cause symptoms such as leg pain, cramping, impaired mobility and reduced quality of life. As treatment options evolve, physicians continue to seek durable solutions that provide sustained vessel patency and favorable long-term outcomes, particularly for patients with complex iliac artery anatomy.
The AGILITY iliac cohort enrolled 120 patients at 28 investigational sites in the United States, Europe, Australia and New Zealand. Through nine months of follow-up, treatment with the Revello™ Vascular Covered Stent resulted in:
Composite safety and effectiveness endpoint met with a failure rate of 2.8%, significantly below the 19% prespecified performance goal 97.2% primary patency 98.3% freedom from clinically driven target lesion revascularization No device- or procedure-related deaths, target limb major amputations (at or above the ankle), or unanticipated serious adverse device effects Patients experienced meaningful gains in daily function and mobility, with mean Rutherford category improving from 3.0 at baseline to 0.3 and mean WIQ score improving by 31.7 points from baseline to 9 months. Women represented approximately 41% of enrolled patients, and slightly more than half of lesions showed moderate-to-severe calcification.
"These latest data showed high primary patency and low clinically driven target lesion revascularization in a patient population that included both straightforward and complex iliac lesions," said Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic and global lead principal investigator for AGILITY. "Results showed the treated arteries remained open in a high percentage of patients, and at nine months, patients also showed changes in disease severity and walking ability."
"These results reflect the continued commitment of BD to advance evidence-based innovation in peripheral vascular care," said Rob Righi, vice president and general manager of the Vascular Platform, Peripheral Intervention at BD. "As follow-up continues, the AGILITY study will help further characterize the Revello™ Vascular Covered Stent's performance across patients with peripheral artery disease."
Clinical follow-up in the iliac cohort is ongoing through 36 months. BD also completed enrollment in the study's superficial femoral and proximal popliteal artery cohort this past August, marking another milestone in the AGILITY study.
The Revello™ Vascular Covered Stent is CE marked. In the United States, the Revello™ Vascular Covered Stent is an investigational device limited by U.S. law to investigational use only.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Od vstupu do indexu Dividend Aristocrats v únoru 2020 přinesla Realty Income celkový výnos pouhých 0,07 %, protože pokles ceny akcií vykompenzoval dividendy.
Realty Income earned one of investing's most coveted quality stamps, yet buyers who celebrated the news found themselves holding a stock that went nowhere for years. The milestones that felt like validation turned out to be traps, and the pattern…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Realty Income (NYSE:O) built its reputation on reliable monthly income. (Seven of our favorite monthly payers are rounded up in this free report.) Among the key milestones discussed here, its first two were excellent entry points; the three that followed were poor ones. Each return below runs from the milestone’s adjusted price to the October 6, 2026, close of $54.25, adjusted for splits and dividends.
A 2013 Buyer Got In Before the Crowd Realty Income closed its American Realty Capital Trust acquisition on January 22, 2013, before it became a household name in the income-investing world. This entry sets the baseline.
Adjusted entry price: $22.20 $1,000 is now worth: $2,443.80 Total return: 144.38% S&P 500 Admission Still Paid Off S&P Dow Jones Indices announced in March of 2015 that Realty Income would replace Windstream Holdings in the S&P 500, effective after the close on April 6, 2015. This entry was strong, though lower than the 2013 one.
Adjusted entry price: $28.50 $1,000 is now worth: $1,903.70 Total return: 90.37% Six Years as a Dividend Aristocrat With Nothing to Show Realty Income announced on January 31, 2020, that it would join the S&P 500 Dividend Aristocrats index on February 3, 2020. The index held 64 components, with Realty Income one of only three real estate investment trusts (REITs) included. Income investors treat that recognition as a quality stamp.
A buyer that day is essentially flat after more than six years with dividends included. For a stock whose case rests on reliable income, a total return near zero means share price decline has offset the dividend stream.
Adjusted entry price: $54.21 $1,000 is now worth: $1,000.70 Total return: 0.07% VEREIT Buyers Got a Spin-Off and Little Else Per PR Newswire, Realty Income closed its VEREIT merger on November 1, 2021, and completed the Orion Office REIT (NYSE:ONL) spin-off and shares began trading on November 15, 2021, so buyers received Orion shares soon after.
Adjusted entry price: $53.15 $1,000 is now worth: $1,020.60 Total return: 2.06% Spirit Deal Buyers Arrived After the Damage Realty Income acquired Spirit Realty Capital on January 23, 2024, after shares had already fallen. That lower starting point made it the best of the three recent entries.
Adjusted entry price: $48.11 $1,000 is now worth: $1,127.60 Total return: 12.76% A Fresh Selloff Weighs on Every Window Measured against a premarket reading of $54.38 on October 7, 2026, trailing performance was:
One week: down 0.89% One month: down 10.77% Year to date: 0.35% One year: down 4.22% Five years: 7.25% Ten years: 47.19% The one-month decline means every milestone return above is measured to a low price.
Recognition Arrived After the Easy Money The milestones that felt like validation were the worst times to buy Realty Income. The entries that worked came either years before recognition or after a selloff had reset the price. Prestige confirmed what the stock had already done; buyers who paid for it were left with dividends and little else.
Contact [email protected] for any questions or corrections.
Eli Lilly's two blockbuster drug approvals that transformed the company into a pharmaceutical giant turned out to be the worst moments to buy the stock. The entry point that crushed every other came during a moment most investors wanted nothing…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Of five key Eli Lilly (NYSE: LLY | LLY Price Prediction) stock entry points, the best by a wide margin was an oncology deal that closed during the financial crisis. The two tirzepatide approvals that built today’s Lilly were the worst. Every return below runs from a milestone’s closing price to the October 6, 2026, close of $1,157.49. Entry prices are split-adjusted (restated so that later share splits leave them comparable) and dividend-adjusted (reduced to credit the payouts a holder collected). Total return means price gain plus dividends, which is what a buy-and-hold investor actually experienced.
Because every return shares one endpoint, the ranking is fixed: a lower adjusted entry price is permanently the better entry, and only the size of each return moves. Here the order is perfectly sequential, with each later milestone proving a worse entry than the one before. (We studied a group of recent runners most investors discounted and pulled out the pattern in a free report here.)
ImClone Bought Cancer Drugs During a Panic Lilly closed its ImClone Systems acquisition on November 24, 2008, as credit markets froze and investors had no appetite for pharmaceutical pipelines. The deal brought Erbitux and an antibody pipeline, giving Lilly a genuine oncology franchise. The broad market bottom was still months away, so this was buying into fear with no guarantee that the selling had ended.
Adjusted entry price: $19.80 $1,000 is now worth: $58,459 Total return: 5,744.43% Trulicity Bridged Old Lilly and New Lilly FDA approval on September 18, 2014, gave Lilly its first major incretin success, a once-weekly diabetes injection that laid the commercial foundation for the later franchise.
Adjusted entry price: $53.99 $1,000 is now worth: $21,439 Total return: 2,043.96% Loxo Extended the Precision Oncology Thread The Loxo Oncology acquisition closed February 15, 2019, adding targeted cancer drugs now sold as Retevmo and Jaypirca. Jaypirca revenue reached $192 million in Q2 2026, up 56% year over year.
Adjusted entry price: $111.48 $1,000 is now worth: $10,383 Total return: 938.28% Mounjaro and Zepbound Built Today’s Lilly and Paid the Least Mounjaro (tirzepatide for diabetes) won approval May 13, 2022. Zepbound, the same molecule for obesity, followed on November 8, 2023. In Q2 2026, they generated $9.94 billion and $4.93 billion, respectively. Tirzepatide’s potential was obvious on both dates, and the market priced it in. Buying into that consensus returned the least.
Mounjaro adjusted entry price: $281.76 $1,000 is now worth: $4,108 Total return: 310.8% Zepbound adjusted entry price: $606.54 $1,000 is now worth: $1,908 Total return: 90.84% Trailing Returns Show Momentum Holding Measured to a premarket quote of $1,163.26 on Wednesday:
Year to date: 8.77% One year: 38.53% Five years: 421.94% Ten years: 1,557.06% What You Paid Mattered More Than How Long You Held Milestone headlines report a move that has already happened. Shares trade near 38x trailing and 24x forward earnings, with 2026 revenue guidance of $85.0 billion to $87.0 billion. Today’s price would be easier to justify if retatrutide, scheduled for a Q1 2027 filing, continues growth. Falling U.S. received prices squeezing the two-drug franchise driving the most revenue would be cause for caution.
Contact [email protected] for any questions or corrections.
Danaher plánuje začátkem roku 2027 spustit autonomní laboratoř využívající AI, která má až osminásobně urychlit vývoj afinitních činidel a až desetinásobně zvýšit jejich roční produkční kapacitu.
Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies
, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow. It is the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research.
Danaher's first AI-powered autonomous lab is designed to deliver:
Speed: Up to 8x faster discovery of affinity reagents, helping researchers get from idea to breakthrough sooner Scale: Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scales Quality: Each design built in the lab would also be verified, tested and fed back to improve the next, without trading speed for scientific rigor Sustainability: Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools "The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver," said Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher. "By applying our science, technology and culture of continuous improvement, we can help turn promising ideas into validated systems faster. It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact."
Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow. The device orchestration and robotic automation is the result of collaborative work with Automata*. This continuous design-make-test-learn loop can run in a fraction of the time it takes today, without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used across Danaher operations to an AI-enabled laboratory environment. The lab is set to be an early proof point for how Danaher's smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress.
"This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle," said JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher. "Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds. The lab is designed to deliver up to eight times faster progress from idea to validated reagent and up to a tenfold increase in reagent generation, while scientists continue to make the key decisions. That frees them to focus on the complex scientific challenges where human insight matters most."
The lab is an example of a broader program across Danaher intended to create a fleet of smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include expert-level agentic systems designed to simplify operation, improve data quality and generate deeper insights. These intelligent devices can then be connected to create integrated workflows and autonomous labs that execute design-make-test-learn cycles. The approach also supports a shift toward more predictive and standardized research workflows, with models helping prioritize the most promising designs before they are made and robotics supporting more consistent experimentation.
The platform reflects an important milestone in the Company's continued investment in connected science at a global scale: technologies designed to help researchers move from scientific question to validated answer with greater speed, consistency and confidence.
FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including statements regarding the Company's AI-powered autonomous lab, the anticipated timing, performance, capabilities and benefits of the platform, the development and deployment of smart instruments, integrated workflows and autonomous labs, and the expected impact of these technologies on biomedical research and scientific discovery, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That's Innovation at the speed of life. Explore more at www.danaher.com.
*Automata received an investment from DHR in Jan 2026
Bundesliga po nasazení CRM systému ServiceNow vyřeší hned při prvním kontaktu 89 % dotazů fanoušků; počet založených případů od začátku sezony klesl o více než 50 %.
Bundesliga, the top professional football league in Germany, has selected ServiceNow (NYSE: NOW), the Super Intelligence Control Tower for business reinvention, as its Official CRM Partner as it deepens its use of ServiceNow’s CRM platform to enhance fan experiences. The partnership adds to ServiceNow's existing role as Official Workflow Partner. Since implementing ServiceNow Customer Service Management in August 2026, Bundesliga has consolidated fan services from seven digital channels onto a single platform, where 89% of fan enquiries are now resolved at first contact. Fans get faster, more consistent answers regardless of which channel they use, while customer service teams now handle less than half the case volume compared to last season.
Bundesliga (formerly DFL Deutsche Fußball Liga) is the association responsible for the organization and marketing of German professional football, namely the top-tier leagues Bundesliga and Bundesliga 2. It connects 36 clubs and reaches fans in more than 200 nations. With this international reach comes a growing demand for fast, consistent and scalable fan services. Previously, enquiries were managed directly within various fan channels such as the Bundesliga app, website, email and social media. With ServiceNow, fan communication is managed through a single CRM platform to enable more consistent and automated responses with a clear view of each fan's history.
Fan cases down more than 50 percent since the season start
ServiceNow CRM captures, categorizes and routes incoming requests through Bundesliga’s service processes to help ensure each request can be managed more efficiently. Recurring questions are answered automatically through a centralized knowledge base. For more complex requests, Now Assist supports customer service teams with case summaries, relevant knowledge content and recommended responses. For fans, this means faster and more consistent answers, regardless of which digital channel they use.
Figures from the first weeks of the season show a clear and positive effect on case volume. The number of fan cases created fell by more than 50%, even though seven intake channels now run on a single platform instead of five. Bundesliga attributes this to the automation of recurring enquiries and the central knowledge base that can answer standard questions before a case is created.
From fan services to a platform for the entire Bundesliga ecosystem
Fan services is only one part of the joint technology roadmap. Bundesliga and ServiceNow plan to extend the platform to additional stakeholders and processes across the Bundesliga ecosystem. This is expected to include digital workflows for external service providers, partners, and the clubs. A centralized club portal, for example, will provide a structured digital interface for requests and services between Bundesliga and its clubs. With ServiceNow, Bundesliga is creating a single platform that connects fans, clubs, partners, and internal teams, while bringing together information and workflows across organizational boundaries.
"The Bundesliga’s success is built on passionate fans, packed stadiums and authentic club cultures. As we continue to innovate digitally, ServiceNow CRM has transformed how we engage with our audience, bringing fan interactions from multiple channels into one intelligent platform. By combining automation and actionable insights, we have achieved first-contact resolution rates of 89% while reducing case volumes by more than half. These capabilities help us strengthen fan relationships at scale and move closer to our vision of becoming the world’s most fan-centric sports league," said Bastian Zuber, Chief Product & Technology Officer of Bundesliga Media.
“Bundesliga is a great example of what happens when you connect the entire customer experience on one intelligent platform,” said Paul Fipps, President, Global Customer Operations at ServiceNow. “They’re resolving 89% of fan inquiries on the first contact by getting every question to the right place with the right knowledge. That’s what makes ServiceNow CRM different. We connect the work behind the customer experience — helping organizations move faster, deliver better experiences, and scale what works.”
Find out more about how Bundesliga and ServiceNow are working together in this video.
About ServiceNow
ServiceNow (NYSE: NOW) is the Super Intelligence Control Tower for business reinvention. The ServiceNow AI Platform integrates with any AI, any cloud, any model, and any data source to orchestrate, govern, and secure work across the enterprise. As the intelligent control tower, ServiceNow gives customers the enterprise context, control, and confidence to scale AI across every corner of business. With more than 100 billion workflows running on the platform each year, ServiceNow helps organizations turn fragmented operations into coordinated, autonomous workflows that deliver measurable results at scale. Learn how ServiceNow puts AI to work for people at www.servicenow.com
The Bundesliga is the premier professional association football league in Germany. Established in 1963, the Bundesliga comprises 18 teams which operate on a system of promotion and relegation with the Bundesliga 2.
In the year 2000, the 36 clubs of the Bundesliga and Bundesliga 2 established a league association, which has been responsible for professional football in Germany ever since and operates under the name Bundesliga e.V. since 2026. The operational business is managed by the Bundesliga Group, based in Frankfurt, which – together with its subsidiaries – is responsible for organizing and marketing German professional football.
Forward Looking Statements
This press release contains “forward-looking statements” about the expectations, beliefs, plans, and intentions relating to ServiceNow’s partnership with Bundesliga. Such statements include statements regarding future product capabilities and offerings and expected benefits to ServiceNow. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, ServiceNow’s results could differ materially from the results expressed or implied by the forward-looking statements made. ServiceNow undertakes no obligation, and does not intend to update the forward-looking statements. Factors that may cause actual results to differ materially from those in any forward-looking statements include: (i) delays and unexpected difficulties and expenses in executing the product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether sales will justify the investments in the product capabilities and offerings. Further information on factors that could affect ServiceNow’s financial and other results is included in the filings ServiceNow makes with the Securities and Exchange Commission from time to time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261006022401/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Skyworks dokončil automobilovou kvalifikaci AEC-Q100 pro izolovaný budič Si829x, který je nyní k dispozici pro odběr vzorků a pokročilé prototypování trakčních měničů elektromobilů.
Si829x platform with ProVCD™ technology moves from development to pre-production release for EV traction inverters | Source: Skyworks Solutions, Inc.
IRVINE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors, today announced that its Si829x isolated safety gate driver with ProVCD™ technology has completed AEC-Q100 automotive qualification and is ready for advanced prototyping. Samples, tools, user guides, and application notes are available now. Designed for scalable, high-performance inverter architectures, the Si829x supports both SiC FETs and IGBTs while helping customers improve efficiency, simplify system design, and reduce system cost in applications ranging from automotive drivetrains to safety-critical electric vertical take-off and landing (eVTOL) systems.
AEC-Q100 Qualified and Ready for Evaluation
With AEC-Q100 qualification completed, the Si829x is now positioned to support customers for initial product evaluation through pre-production prototypes. Samples are available today, giving customers a qualified, prototype-ready path to design-in.
The Si829x was designed to support customer functional safety system designs rated up to ASIL D, subject to system-level implementation and validation, to deliver the robustness required for EV traction inverters and other safety critical motor control applications. Its integrated protection features include:
Extensive diagnostic fault coverage, notification and managementComprehensive safety mechanisms including power-up self-checks and safe state enforcement – a functional safety manual is available todayAdvanced isolation technology certified by multiple independent organizations for enhanced safety and reliability With applications in battery electric vehicles, hybrid electric vehicles, eAgriculture, eTrucking, robotaxis, and exciting new segments like eVTOL aircraft, Si829x is a comprehensive choice among isolated gate drivers for safety-critical advanced propulsion systems.
Full Documentation and Development Tools Now Available
Alongside qualification, Skyworks has prepared the complete technical resource set for the Si829x, including datasheet, technical reference manual, functional safety manual and application notes. This resource set, available under NDA, gives design teams comprehensive technical documentation to evaluate, integrate and validate the part.
Skyworks has also released customer-facing development tools, including two evaluation board kits, companion GUI software and complex device driver (CDD) software, designed to shorten development cycles and reduce time-to-market.
A New Approach to Gate Drive Control
Unlike conventional voltage-mode gate drivers, the Si829x uses ProVCD™, which is Skyworks’ second-generation variable current drive that delivers high resolution gate waveform shaping and cycle-by-cycle control through a digital interface. This approach enables:
Precise 15 Amp 3-phase turn-on and turn-off current waveform controlSwitching-loss reductions of up to 44% in Skyworks testing, compared with voltage-mode gate driveReduced electromagnetic interference (EMI) and filtering requirementsImproved thermal efficiency through multiple packaging optionsSmaller PCB footprint and potential system-level cost savings Together, these benefits allow manufacturers to increase inverter efficiency while simplifying system design and accelerating development cycles.
“Si829x gives customers a qualified path from evaluation to advanced prototypes,” said Mario Battello, vice president of product line management at Skyworks. “The ProVCD™ platform combines software-configurable performance with the safety, isolation and design flexibility needed to standardize inverter designs for EVs, eVTOL, and eAgriculture, and accelerate development for high power motor applications like datacenter cooling and AI power supplies.”
Platform Scalability and Design Flexibility
The Si829x is designed as a configurable platform, allowing engineers to adjust gate drive parameters through software rather than fixed hardware components. This configurability supports:
Design reuse across multiple vehicle platformsFaster development and validation cyclesGreater flexibility to optimize performance, efficiency and costVendor-agnostic compatibility across power semiconductor technologies By supporting both SiC FETs and IGBTs within a single gate driver platform that integrates a VPOS regulator, bipolar gate drive voltages are provided without the need for additional, external bias supplies.
Si829x availability
The Si829x platform is now available for sampling. To learn more, including product features, package options and design resources, visit skyworks.com/go/si829x.
About Skyworks
Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.
From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world's leading innovators bring next-generation products and services to market.
Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworks.com.
Safe Harbor Statement
Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties including, but not limited to, our ability to timely and accurately predict market requirements and evolving industry standards and to identify opportunities in new markets; our ability to develop, manufacture, and market innovative products and avoid product obsolescence; our ability to compete in the marketplace and achieve market acceptance of our products; the level of widespread deployment or adoption of commercial 5G networks, AI and other new technologies; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials and supplier components; the quality of our products; our products’ ability to perform under stringent operating conditions; and other risks and uncertainties identified in the “Risk Factors” section of Skyworks' most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks' SEC filings can be obtained, free of charge, on Skyworks' website (www.skyworksinc.com) or at the SEC's website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Note to Editors: ProVCD™, SelVCD™, Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.
AUSTIN, Texas--(BUSINESS WIRE)--CrowdStrike (NASDAQ: CRWD) today announced it has been named a Leader in the IDC MarketScape: Worldwide Modern Endpoint Security for Enterprises 2026 Vendor Assessment.1
AI is now part of every enterprise, and the endpoint is where agents act autonomously at machine speed with system-level privilege. CrowdStrike pioneered AI-native EDR and is defining what customers need to secure AI with AI Detection and Response (AIDR). CrowdStrike's AIDR business has grown more than 79-fold2 in three quarters since launch, with Falcon Guardian securing AI agents at the point of execution.
“CrowdStrike pioneered this market, and the world's leading organizations trust the Falcon platform to stop breaches,” said AJ Shipley, chief product officer at CrowdStrike. “Deployed across hundreds of millions of devices and powered by cybersecurity’s richest data set, CrowdStrike has the structural advantage to lead as AI becomes the new attack surface. We secure AI where it executes, on the endpoint at runtime, and we believe this recognition reflects how we continue to define the future of security.”
Giving Defenders the AI Advantage
As adversaries weaponize AI and compress the defender’s window to respond, the report notes “every vendor in this market now markets AI, so the question is no longer whether AI is present but whether it is applied where it changes outcomes.” CrowdStrike’s profile notes some key strengths including “deep AI and agentic investment translating into reported SOC efficiency gains, backed by a very large real-time telemetry pipeline processing trillions of events daily.”
One Unified Platform to Stop Cross-Domain Attacks
AI-driven threats don’t stay on the endpoint; they target every domain at once. CrowdStrike’s unified architecture extends real-time protection across the enterprise. The IDC MarketScape noted another key strength: “broad, natively delivered platform spanning endpoint, identity, cloud, data, exposure management, and increasingly browser and mobile security, reducing reliance on third-party point products.”
To learn more about why CrowdStrike has been named a Leader in the IDC MarketScape: Worldwide Modern Endpoint Security for Enterprises 2026 Vendor Assessment, visit here.
About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About CrowdStrike
CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.
Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft, and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting, and prioritized observability of vulnerabilities.
Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity, and immediate time-to-value.
CrowdStrike: We stop breaches.
Learn more: https://www.crowdstrike.com/
Follow us: Blog | X | LinkedIn | Instagram
Start a free trial today: https://www.crowdstrike.com/trial
Akcie The Trade Desk v září klesly o 11 % poté, co firma oznámila restrukturalizaci, v jejímž rámci sníží počet zaměstnanců přibližně o 15 %, a vyřazení z indexu S&P 500.
The Trade Desk (TTD -0.50%) was the wrong kind of busy in September. The next-generation adtech company didn't look like a business primed for the future after announcing a restructuring plan, witnessing a rival score a high-profile client, and being booted from a major stock index, among other setbacks.
Last month was a blustery one full of headwinds for The Trade Desk, so perhaps it's lucky to have exited September with "only" an 11% decline in its share price. Yet I think it could go lower. Before we get to that, however, let's recap the company's not-so-good month.
Image source: Getty Images.
Restructurings and roadblocksSeptember didn't start on an encouraging note for The Trade Desk. Numerous media outlets, citing a company statement, reported that it planned to cut its workforce by roughly 15% as part of a broader restructuring effort. The company effectively confirmed this in a regulatory filing, in which it estimated that such moves would result in charges of around $39 million to $51 million, offset by a reversal of approximately $4 million to $5 million in stock-based compensation. There was clearly some urgency to this for The Trade Desk, as it expressed a desire to complete the process by the beginning of the third quarter (i.e., the start of October).
Also, early in the month, The Trade Desk was removed from the benchmark S&P 500 index. In a quarterly rebalancing by the index's operator, S&P Dow Jones Indices, the company's stock was shifted to the S&P SmallCap 600 Index. Such was the effect of a shrinking price and, therefore, market cap, on the beaten-down stock.
As if these body blows weren't enough, its rival Amazon (AMZN +1.95%) Ads announced a new advertising partnership with top artificial intelligence (AI) developer OpenAI. Under its terms, Amazon Ads clients will have the option to expand their campaigns into conversational experiences using OpenAI's ChatGPT model. Amazon added that select advertisers, which it did not name, were testing this service in a pilot program.
Finally, at the end of the month, industry website Ad Exchanger published a story stating that The Trade Desk was unable to serve ads to Apple's (AAPL +0.22%) Safari browser in certain instances. The problem, apparently, was the tech company's iOS 27, the latest iteration of its operating system. Ad Exchanger said Apple was investigating the issue. As of this writing, the situation had not been resolved.
Premium Feature
Moneyball Superscore
90/100
Today's Change
(
1.95
%) $
4.89
Current Price
$
256.29
A September not to rememberThe Trade Desk has shown resiliency in the past, so I wouldn't underestimate its ability to rebound. Yet that seemingly urgent restructuring project indicates a company scrambling to avoid trouble, and Amazon Ads looks like it might be a tough competitor with abundant resources. It doesn't feel to me like The Trade Desk has a sufficient moat, so it's vulnerable. I believe we might not be seeing the bottom for this stock yet.
FuelCell Energy jmenovala Matthewa Latina finančním ředitelem s účinností od 7. října 2026; Michael Bishop bude působit jako seniorní poradce do výroční valné hromady v roce 2027.
Matthew Latino appointed CFO; Michael Bishop to continue as senior advisor | Source: FuelCell Energy, Inc.
DANBURY, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) today announced that Michael Bishop will transition from his role as Executive Vice President, Chief Financial Officer and Treasurer of the Company. Matthew Latino will succeed him as Executive Vice President, Chief Financial Officer and Treasurer effective October 7, 2026, as part of a planned transition. Bishop, who has served as the Company’s CFO for 15 years during an overall tenure with the Company of more than two decades, will remain with FuelCell Energy as a senior advisor through the Company’s 2027 Annual Meeting of Stockholders to support continuity and the transition.
FuelCell Energy also reaffirmed its previously stated target of achieving positive Adjusted EBITDA results in the fourth quarter of fiscal 2027, subject to the planned increase in annualized production rate, the conversion of awarded capacity backlog into committed backlog, customer delivery schedules and continued execution of the Company’s cost reduction initiatives. The Company remains focused on converting its growing commercial pipeline—driven by demand for reliable, always-on power for AI and data center infrastructure—into durable growth, while scaling manufacturing, advancing customer financing structures and maintaining disciplined capital allocation, liquidity and balance sheet strength.
“Mike has been a steward of this Company through every stage of its journey,” said Jason Few, President and Chief Executive Officer. “Over more than two decades, he led our finance organization through periods that tested our business and our industry while maintaining a clear focus on financial discipline, integrity, the long-term interests of the business, and our commitment to shareholders. His leadership across capital formation, project finance and balance sheet management strengthened our financial foundation and supported the evolution of our strategy. I am grateful for his service and pleased that we will continue to benefit from his perspective during the transition.”
“Serving as CFO of FuelCell Energy has been one of the great privileges of my career,” said Bishop. “I am proud of what our finance team and our colleagues across the Company have accomplished together and of the strong foundation we have built. I have tremendous confidence in Jason, the leadership team, and the Board, and I look forward to supporting a seamless transition and sharing in the Company’s success as a continuing shareholder.”
Latino joins FuelCell Energy from Xylem Inc. (NYSE: XYL), where he served as Senior Vice President, Finance and Segment Chief Financial Officer of its approximately $2 billion Measurement & Control Solutions business. He previously led Xylem’s investor relations function, giving him direct experience engaging the investment community and communicating strategy, performance and long-term value creation. Latino began his career at Deloitte & Touche LLP.
“As we scale, our responsibility to shareholders is to grow with discipline-every megawatt we build and every dollar we deploy must compound value,” Few said. “Matt has led finance for a large-scale industrial technology business, partnered with operating leaders to drive performance, and led investor relations for a global public company. He understands how the market measures execution and how to build the operating rhythm that delivers it. We believe he is the right leader to help us convert a significant commercial opportunity into durable shareholder value.”
“I am honored to join FuelCell Energy at an important point in the Company’s evolution,” said Latino. “The Company has a differentiated technology platform, a strong financial foundation and clear strategic priorities. I look forward to partnering with Jason, the leadership team and the Board to build on the foundation Mike helped establish, maintain rigorous financial discipline, and support the execution and investment decisions required to scale the business and create sustainable value.”
FuelCell Energy, Inc. (Nasdaq: FCEL) is an American clean energy technology company delivering continuous, scalable baseload power for mission-critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.FuelCellEnergy.com.
Cautionary Language
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or our future financial performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, statements with respect to the Company’s anticipated financial results and statements regarding the Company’s plans and expectations regarding the continuing development, commercialization and financing of its current and future fuel cell technologies, the Company’s business plans and strategies, the Company’s plan to reduce operating costs, the capabilities of the Company’s products, the Company’s plans and ability to achieve positive Adjusted EBITDA, subject to the planned increase in annualized production rate, the conversion of awarded capacity backlog into committed backlog, customer delivery schedules and continued execution of the Company’s cost reduction initiatives, the Company’s potential sales pipeline, opportunities, and partners, and the markets in which the Company expects to operate. Projected and estimated numbers contained herein are not forecasts and may not reflect actual results. These forward-looking statements are not guarantees of future performance, and all forward-looking statements are subject to risks and uncertainties, known and unknown, that could cause actual results and future events to differ materially from those projected. Factors that could cause such a difference include, without limitation: general risks associated with product development and manufacturing; general economic conditions; changes in interest rates, which may impact project financing; supply chain disruptions; changes in the utility regulatory environment; changes in the utility industry and the markets for distributed generation, distributed hydrogen, and fuel cell power plants configured for carbon capture or carbon separation; potential volatility of commodity prices that may adversely affect our projects; availability of government subsidies and economic incentives for alternative energy technologies; our ability to remain in compliance with U.S. federal and state and foreign government laws and regulations; our ability to maintain compliance with the listing rules of The Nasdaq Stock Market; rapid technological change; competition; the risk that our bid awards (or other non-binding commitments) will not convert to contracts or that our contracts will not convert to revenue; market acceptance of our products; changes in accounting policies or practices adopted voluntarily or as required by accounting principles generally accepted in the United States; factors affecting our liquidity position and financial condition; government appropriations; the ability of the government and third parties to terminate their development contracts at any time; the ability of the government to exercise “march-in” rights with respect to certain of our patents; our ability to successfully market and sell our products internationally; delays in our timeline for bringing commercially viable products to market; our ability to develop additional commercially viable products in the future; our ability to implement our strategy; our ability to reduce our levelized cost of energy and deliver on our cost reduction strategy generally; our ability to protect our intellectual property; litigation and other proceedings; the risk that commercialization of our new products will not occur when anticipated or, if it does, that we will not have adequate capacity to satisfy demand; our need for and the availability of additional financing; our ability to generate positive cash flow from operations; our ability to service our long-term debt; our ability to increase the output and longevity of our platforms and to meet the performance requirements of our contracts; our ability to expand our customer base and maintain relationships with our largest customers and strategic business allies; our ability to reduce operating costs; and our ability to achieve positive Adjusted EBITDA in the future, as well as other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025. The forward-looking statements contained herein speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement contained herein to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.
Američtí žalobci použili verdikt v kauze Bitcoin Fog na podporu argumentu, že používání Tornado Cash na Manhattanu zakládá místní příslušnost soudu v New Yorku v případu Romana Storma.
Federal prosecutors cited a recent appeals court ruling involving cryptocurrency mixer Bitcoin Fog as supplemental authority for their opposition to Tornado Cash developer Roman Storm’s acquittal.
In a Monday filing, prosecutors cited a Sept. 25 appeals court ruling that affirmed the convictions and sentence of Bitcoin Fog operator Roman Sterlingov.
The D.C. Circuit held that venue in Washington, D.C., was proper for all four counts. For the money-laundering counts, it relied on evidence that an undercover agent conducted Bitcoin Fog transactions from his D.C. office. For the unlicensed money-transmission counts, it found sufficient evidence that Bitcoin Fog had served customers in the district.
Prosecutors said the Bitcoin Fog ruling “directly supports” their position in Storm’s case, arguing that Tornado Cash activity in Manhattan was sufficient to establish venue in the Southern District of New York for Storm’s money-laundering and unlicensed money-transmission conspiracy charges. They pointed to testimony from Shakeeb Ahmed, who said he used Tornado Cash from his Manhattan apartment.
Judge Katherine Polk Failla heard arguments on Storm’s acquittal motion in April 2026 and has not yet ruled. A retrial on the money-laundering and sanctions conspiracy counts on which the jury deadlocked is scheduled for April 26, 2027, if those charges remain pending.
A jury convicted Storm in August 2025 of conspiring to operate an unlicensed money-transmitting business but deadlocked on the money-laundering and sanctions-conspiracy charges. Storm filed his post-trial motion for acquittal in September 2025, arguing that prosecutors failed to prove he intended to help criminals misuse Tornado Cash.
DOJ leans on Bitcoin Fog ruling in New York argumentIn his 2025 acquittal motion, Storm argued that Ahmed’s use of Tornado Cash from his Manhattan apartment was not enough to establish venue in New York because the transactions did not further the alleged conspiracy.
Prosecutors argued that even short-lived deposits can help a mixer by increasing the pool of transactions used to obscure the movement of funds. They said that reasoning applies to Ahmed’s Tornado Cash activity and supports their argument that his use of the service furthered the alleged conspiracy.
Storm criticized the filing in an X on Monday, saying, “The DOJ is still coming after me with everything it has.”
He also cited the Treasury Department’s Monday announcement that it would withdraw its proposed crypto-mixer rule, arguing that the government is taking conflicting approaches to crypto privacy tools.
Magazine: US crypto rules need to survive the next election
Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently.
More than 175 biotechs use pre-configured applications to streamline operations
, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effort, and cost.
"As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics. "Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance."
Biotechs are leveraging Veeva Basics to drive new ways of working, including shifting regulatory publishing strategies from outsourced to insourced. Veeva Submissions Publishing Basics provides a modern application for submission building and health authority interactions that equips regulatory teams to bring publishing in-house. For biotechs preparing to publish their first submissions to the FDA, Veeva Basics enables them to hit critical regulatory milestones with improved visibility and control across the entire regulatory lifecycle.
"Insourcing our submission publishing through Veeva Basics gave us sharper quality control and significantly faster regulatory timelines," said Darryl Clarke, global head, regulatory operations at Structure Therapeutics. "We have modern applications with global support to execute quickly now, and the flexibility to scale in the future."
"Biotechs are responsible for so much of the innovation shaping the industry and they need technology that reflects the pace that they operate in," said Jim Thai, vice president, Veeva Basics. "It's been a privilege to work with industry pioneers and build this community of Veeva Basics customers advancing drug development."
Built on the proven Vault Platform, Veeva Basics applications help customers to scale their technology infrastructure seamlessly as they grow. For more on Veeva Basics, visit veevabasics.com, or register for Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Centene bude od roku 2027 prostřednictvím Ambetter Health Solutions nabízet oprávněným pojištěncům v částech Indiany a Missouri bezplatné návštěvy praktického lékaře, laboratorní služby a virtuální péči od společnosti Marathon Health.
Marathon Health logo The new partnership will provide eligible members with $0 primary care visits, lab services, and virtual care beginning in 2027
, /PRNewswire/ -- Centene Corporation (NYSE: CNC), through Ambetter Health Solutions, today announced a new collaboration with Marathon Health, a leading advanced primary care provider, designed to make primary care easier to access for Ambetter members in select counties across Indiana and Missouri. Available through CHOICE Arrangements (formerly ICHRA), eligible members will have access to $0 primary care visits and lab services, along with virtual primary care through Marathon Health.
"Strong primary care can help identify health concerns earlier and give Ambetter's CHOICE members the support they need to manage their health over time," said Alan Silver, President of Ambetter Health Solutions. "By combining the flexibility of CHOICE Arrangements with Marathon Health's advanced primary care model, we're making it easier for employers to offer meaningful healthcare access while helping members get the preventive care, chronic condition support and ongoing provider relationships that can improve long-term health outcomes."
Marathon Health's advanced primary care model brings together in-person and virtual care with services such as lab testing, chronic condition support, mental health services, and help navigating the healthcare ecosystem. This coordinated approach is designed to provide a simpler member experience and help address health needs before they become severe. By building trust and delivering care earlier, Marathon's model has demonstrated measurable impact among engaged members: 15% fewer emergency room visits and 41% fewer inpatient admissions.
"Access to primary care shouldn't be complicated, and it shouldn't come with barriers that make people delay the care they need," said Ryan Jacobs, Senior Vice President, Strategy & Partnerships, Marathon Health. "This collaboration gives Ambetter members in Indiana and Missouri a direct path to the kind of consistent, trusted provider relationships that keep people healthier and out of high-cost care settings."
Eligible members will receive information about available services and how to access care prior to the beginning of the 2027 plan year. To learn more about advanced primary care for health plans, visit Marathon Health.
About Ambetter Health Solutions
Ambetter Health Solutions, Centene Corporation's off-Exchange Marketplace business offering, delivers individual health insurance plans that are compatible with Individual Coverage Health Reimbursement Arrangements (ICHRA). Available in select states, including Arizona, Florida, Georgia, Ohio, Indiana, Missouri, Mississippi, Kansas, Nebraska, Oklahoma, Tennessee, Texas and South Carolina, these plans empower individuals to choose the coverage that best fits their needs, helping employers control cost while offering greater choice and flexibility to their workforce. For more information on health benefits and health insurance plans in your state, please visit the state specific link on AmbetterHealth.com.
About Marathon Health
Marathon Health is a leading advanced primary care provider, partnering with employer and union plan sponsors, as well as health plans, to improve health for millions of Americans. With nationwide onsite, nearsite, and network health centers, and virtual primary care, Marathon delivers a value-based model that enhances the healthcare experience for members and providers, while driving meaningful cost savings for plan sponsors. Marathon is proud to be certified as a Great Place to Work®, reflecting the company's commitment to building an inclusive, high-trust culture where all employees can thrive. Learn more at marathon.health.
